

2010 Fact Book

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

2010 Fact Book

The information set forth in this publication is compiled and amended annually by the budget and finance staff of the National Cancer Institute and is intended primarily for the use by members of the Institute and others involved in the administration and management of the National Cancer Program.

Questions regarding any of the information contained herein may be directed to the Office of Budget and Finance, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892

This document is also available online on the Office of Budget and Finance homepage (http://obf.cancer.gov/) on the National Cancer Institute's website (http://www.cancer.gov).

TABLE OF CONTENTS

Executive Summary	Fiscal Year 2010 Annual Report	iii
Organization	Director's Biography	O-1
3	Former Directors of the NCI	
	National Cancer Advisory Board	
	Boards of Scientific Counselors and Advisors	
	President's Cancer Panel	
	Scientific Program Leaders	
	Clinical Trials and Translational Research Advisory Commit	
	NCI Director's Consumer Liaison Group	
	Operational Organization Charts:	
	National Cancer Institute	0-14
	Office of the Director	
	OD I: Office of Management	
	OD II: Center for Biomedical Informatics and Information	
	Technology	0-17
	OD II: Office of Science Planning and Assessment	
	OD III: Office of Communications and Education	
	OD IV: Center to Reduce Cancer Health Disparities	
	OD IV: Center for Strategic and Scientific Initiatives	
	Center for Cancer Research	
	Division of Cancer Biology	
	Division of Cancer Epidemiology and Genetics	
	Division of Cancer Prevention	
	Division of Cancer Control and Population Sciences	
	Division of Cancer Treatment and Diagnosis	
	Division of Extramural Activities	
Cancer Statistics	Links to Cancer Statistics	C-1
Budget Data	NCI Budget	B-1
3	Program Structure	
	Extramural Funds	
	NCI Obligations by Mechanism	
	Division Obligations by Mechanism	
	NIH Management Fund, Service & Supply Fund and GSA R	ent B-6
	Special Sources of Funds	
	Funding for Various Research Areas	
Extramural Programs	Research Project Grants:	
	Number of Awards	E-1
	Requested and Awarded	E-2
	Awards by Activity Code	E-3
	Activity Code Descriptions	
	Cancer Centers	 '
	By State	F-5
	Specialized Programs of Research Excellence (SPORE)	
	National Research Service Awards – Pre and Post Doctoral	
	Trainees	
	a	······ 🗀 /

	Construction/Renovation and Building & Facilities Funding Grant and Contract Awards by State	
	Grant and Contract Awards by Country Institutions Receiving More than \$15,000,000 in NCI Support	
Historical Trends	Appropriations of the NCI	H-1
	Bypass Budget Requests	H-2
	Comparison of NCI Bypass Requests and Appropriations	
	Comparison of Dollars, Positions and Space	
	Personnel Resources	
	AIDS Funding History	
	•	

Fiscal Year 2010 Annual Report

BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2010 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (http://www.cancer.gov).

Summary

Funds available to the NCI in FY 2010 totaled over \$5.098 billion, reflecting an increase of 2.6% and \$131 million from the previous fiscal year.

Fiscal highlights from FY 2010 include:

- Of the total NCI budget, 43% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,079 (includes SBIR).
- Almost one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- 1,253 competing RPGs were funded.
- Almost one-third of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- R01 grants were funded to the 15th percentile.
- 207 grants totaling almost \$86 million were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research comprised just under 16% of the total NCI budget in FY 2010. Of this amount, 10% was for Labs and Bench Research and 5.8% was for infrastructure and support.

NCI Dollars by Mechanism for FY 2009 and 2010 (in thousands)

			Change '09	9 to '10
	2009	2010	Am't	%
Research Project Grants:				
Noncompeting	1,550,906	1,536,844	-14,062	-0.9%
Admin Supplements	33,257	28,947	-4,310	-13.0%
Competing	457,834	516,598	58,764	12.8%
Subtotal, RPG	2,041,997	2,082,389	40,392	2.0%
SBIR/STTR	91,954	85,669	-6,285	-6.8%
Total, RPG	2,133,951	2,168,058	34,107	1.6%
Cancer Centers	285,608	295,856	10,248	3.6%
SPOREs	131,360	133,810	2,450	1.9%
Other P50s/P20s	28,105	38,765	10,660	37.9%
Other Specialized Centers	116,380	142,702	26,322	22.6%
Total: Centers, Spec Ctrs, & SPOREs	561,453	611,133	49,680	8.8%
Research Career Program	79,120	74,914	-4,206	-5.3%
Cancer Education	31,945	35,444	3,499	11.0%
Clinical Cooperative Groups	234,531	254,487	19,956	8.5%
Other Grants	71,698	77,768	6,070	8.5%
Subtotal, Other _	417,294	442,613	25,319	6.1%
Total, Research Grants	3,112,698	3,221,804	109,106	3.5%
National Research Service Awards	70,134	67,564	-2,570	-3.7%
R&D Contracts	610,142	613,762	3,620	0.6%
Intramural Research	781,389	805,332	23,943	3.1%
Research Management & Support	384,644	381,765	-2,879	-0.7%
Construction	-	-	-	0.0%
Buildings and Facilities	7,920	7,920	-	0.0%
Total, NCI	4,966,927 *	5,098,147 **	131,220	2.6%
AIDS research included above	[265,882]	[272,130]	6,248	2.3%

^{*}Cancer Prevention and Control w as eliminated as a Budget Mechanism in FY09.


^{**}EXCLUDES projects aw arded with Stamp Out Breast Cancer funds.

Percent Share of Total NCI Dollars

Summary Points

 The mechanism shares of the total budget have remained relatively stable from FY 2006 to FY 2010, taking into account the elimination of Cancer Prevention and Control as a budget mechanism in FY 2009

Percent Share of Total NCI Dollars					
	2006	2007	2008	2009	2010
Research Project Grants	45.4%	44.1%	43.3%	43.0%	42.5%
Cancer Centers	5.6%	5.7%	5.7%	5.8%	5.8%
SPOREs	2.6%	2.6%	2.6%	2.6%	2.6%
Specialized Centers	1.6%	1.6%	1.6%	2.3%	2.8%
Other P50s/P20s	-	-	-	0.6%	0.8%
Clinical Cooperative Groups	3.1%	3.1%	3.0%	4.7%	5.0%
R&D Contracts	7.3%	8.7%	9.2%	12.3%	12.0%
Intramural Research	14.5%	14.7%	14.9%	15.7%	15.8%
Cancer Prevention & Control*	10.7%	10.4%	9.9%	0.0%	0.0%
Other Mechanisms	9.3%	9.2%	9.9%	13.0%	12.7%
*Cancer Prevention and Control Eliminated as a Budget Mechanis	m in FY09.				



Funding Trends

Summary Points

- The NCI budget has increased by \$350.9 million or 7.4% since FY 2006.
- Increase for R&D contracts, Clinical Cooperative Groups, and other mechanisms are due in part to the elimination of the Cancer Prevention and Control Mechanism

Н	Historical Funding Trends								
	(Dollars in Millions)								
2006 2007 2008 2009 2010									
Total NCI	\$4,747.2	\$4,792.6	\$4,827.6	\$4,966.9	\$5,098.1				
Research Project Grants	2,156.9	2,111.8	2,089.9	2,134.0	2,168.1				
Cancer Centers	265.0	273.2	274.5	285.6	295.9				
SPOREs	124.9	123.8	123.3	131.4	133.8				
Other P50s/P20s	-	-	-	28.1	38.8				
Other Specialized Centers	73.9	74.7	79.3	116.4	142.7				
Clinical Cooperative Groups	145.9	148.2	144.0	234.5	254.5				
R&D Contracts	347.8	416.9	444.2	610.1	613.8				
Intramural Research	687.3	706.2	718.4	781.4	805.3				
*Cancer Prevention & Control	505.6	498.4	471.5	-	-				
Other Mechanisms	439.8	439.4	482.5	645.5	645.4				

% Growth by Mechanism							
	2006 to 2007	2007 to 2008	2008 to 2009	2009 to 2010	2006 to 2010		
Total NCI	1.0%	0.7%	2.9%	2.6%	7.4%		
Research Project Grants	-2.1%	-1.0%	2.1%	1.6%	0.5%		
Cancer Centers	3.1%	0.5%	14.3%	3.6%	11.6%		
SPOREs	-0.9%	-0.4%	6.5%	1.9%	7.1%		
Other P50s/P20s	-	-	100.0%	37.9%	100.0%		
Specialized Centers	1.0%	6.2%	46.8%	22.6%	93.0%		
Clinical Cooperative Groups	1.6%	-2.8%	62.9%	8.5%	74.4%		
R&D Contracts	19.9%	6.6%	6.6%	0.6%	76.5%		
Intramural Research	2.7%	1.7%	8.8%	3.1%	17.2%		
*Cancer Prevention & Control	1.4%	-5.4%	-100.0%	0.0%	-100.0%		
Other Mechanisms	-0.1%	9.8%	33.8%	0.0%	46.7%		

 $^{^{\}star}\text{Cancer}$ Prevention and Control Eliminated as a Budget Mechanism in FY09.

Research Project Grants


Summary Points

- 91% of competing dollars supported grants awarded within the established payline; 9% supported grants as an exception to the payline.
- RFA funds increased from FY 2009 dollar level and accounted for 12.6% of FY 2010 competing dollars.
- Research Project Grant applications submitted to NCI increased by approximately 14%.
- A total of 1,253 competing RPG's were funded.

Research Project Grants* (Dollars in Thousands)						
	2009 2010					
	No.	A mount	No.	Amount		
Total funding for RPGs	5,179	\$2,133,951	5,078	\$2,169,058		
SBIR/STTR	261	\$91,954	207	\$85,669		
Funding for RPGs without SBIR/STTR Program	4,918	\$2,041,997	4,871	\$2,082,389		
Competing grants funded	1,235	\$457,834	1,253	\$516,598		
Administrative Supplements	267	\$33,257	258	\$29,022		
Partial assessment for DHHS Program Evaluation		\$70,912		\$75,329		
Funds set aside within competing dollars for:						
Grants within Paylines:	1,169	\$423,668	1,134	\$468,594		
Traditional R01	680	\$259,819	726	\$284,237		
Program Projects (P01)	23	\$39,339	26	\$53,174		
RFA Grants	89	\$49,001	95	\$65,168		
Share of competing grant funds		10.7%		12.6%		
Exception Grants	66	\$34,165	119	\$48,004		
Share of competing grant funds		7.5%		9.3%		
Competing Application Requests	6,419	\$2,570,862	7,338	\$3,065,725		
Funding Success Rate		19.2%		20.2%		
Percentile funding for R01 grants		16th		15th		
Average Cost-Competing		\$371		\$412		
Average Reduction from recommended/requested						
levels		-17%		-17%		
*EXCLUDES projects aw arded w ith Stamp Out Breast Cancer	funds.					

Grant Funding Paylines						
RPG Mechanisms:	2009	2010**				
R01 Traditional Grants	16th	15th	percentile			
P01 Program Projects*	N/A	N/A	priority score			
R03 Small Grants	210	30	priority score			
R21 Exploratory Phase I	16th	15th	percentile			
R33 Exploratory Phase II	155	17	priority score			
R41/R42 STTR	180	29	priority score			
R43/R44 SBIR	210	29	priority score			

^{*} Formal paylines for P01 grants are determined by the Executive Committee ** In FY 2010, NIH instituted a new peer review scoring system resulting in a two digit priority score. More information on the new system is available under "Peer Review Process" online at: http://grants.nih.gov/grants/oer.htm




National Cancer Institute Extramural vs. Inhouse Funding

(dollars in millions)

Extramural								
Mechanism	2006	2007	2008	2009	2010	06-10% chg.		
Research Project Grants	\$2,156.9	\$2,111.8	\$2,089.9	\$2,134.0	\$2,168.1	0.5%		
Cancer Centers	265.0	273.2	274.5	285.6	295.9	10.4%		
SPOREs	124.9	123.8	123.3	131.4	133.8	6.6%		
Other P50s/P20s	-	-	-	28.1	38.8	100.0%		
Other Specialized Centers	73.9	74.7	79.3	116.4	142.7	48.2%		
Other Research Grants	327.1	322.9	317.8	417.3	442.6	26.1%		
NRSA	66.6	68.2	69.9	70.1	67.6	1.4%		
R&D Contracts	347.8	416.9	444.2	610.1	613.8	43.3%		
Cancer Control Grants*	213.5	200.1	190.4	-	-	-100.0%		
Cancer Control Contracts*	137.1	133.7	134.8	-	-	-100.0%		
Construction	-	-	-	-	-	0.0%		
Buildings & Facilities	7.9	7.9	7.9	7.9	7.9	0.0%		
Total Extramural Funds	3,720.7	3,733.2	3,732.0	3,800.9	3,911.1	5.1%		

Inhouse								
Mechanism	2006	2007	2008	2009	2010	06-10% chg.		
Intramural Research	\$687.3	\$706.2	\$718.4	\$781.4	\$805.3	17.2%		
RMS	184.1	188.7	231.0	384.6	381.8	107.4%		
Control Inhouse*	155.0	164.5	146.3	-	-	-100.0%		
Total Inhouse Funds	1,026.5	1,059.4	1,095.7	1,166.0	1,187.1	15.6%		
Total NCI	4,747.2	4792.6	4,827.7	4,966.9	5,098.1	7.4%		
*Cancer Prevention and Control Eliminated as a Budget Mechanism in FY09.								




Research Career Awards - "K" Program

Summary Points

- The Research Career Award mechanism decreased by 5.3% in FY 2010.
- The number of Research Career Awards decreased by 47 between FY 2009 and FY 2010.
- NCI funded 41 awards for the NIH Pathway to Independence program.

	(Dollars in Thousands)				
	,	20	2009 2010		
		No.	A mount	No.	Amount
K01	Temin Awards	47	\$7,170	30	\$4,520
K01	Minority Mentored Career Development Award	49	6,576	47	6,303
	Subtotal, K01s	96	13,746	77	10,823
K05	Research Scientist Award	20	2,926	21	3,134
K07	Preventive Oncology	108	14,585	97	13,278
K08	Clinical Investigator	85	11,779	83	12,407
K12	Institutional Clinical Oncology Research	17	11,643	18	12,922
K22	Transition Career Development	43	6,763	30	4,963
K23	Patient-Oriented Career	44	6,179	40	5,812
K24	Patient-Oriented Career Mid Career	18	2,916	20	3,422
K25	Mentored Quantitative Research Career Development Award	22	3,087	25	3,311
K99	NIH Pathway to Independence Awards	46	5,496	41	4,842
	Total Research Career Program	499	79,120	452	74,914



Research Dollars by Various Cancers

Summary Points

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget
- Based on NCI Coding Methodology.

Research Dollars by Various Cancers						
	(Dollars	in Millions)				
_	2006	2007	2008	2009	2010	
Total NCI	\$4,747.2	\$4,792.6	\$4,827.6	\$4,966.9	\$5,098.1	
AIDS	253.7	253.7	258.5	265.9	272.1	
Brain & Central Nervous System	130.3	148.2	153.7	151.5	156.8	
Breast Cancer	584.7	572.4	586.8	599.4	631.2	
Cervical Cancer	83.3	82.4	76.8	70.8	77.0	
Clinical Trials	822.3	843.7	853.2	882.8	852.3	
Colorectal Cancer	244.1	258.4	273.7	264.1	270.4	
Head and Neck	71.3	66.2	76.1	77.1	62.7	
Hodgkin's Disease	20.9	16.5	17.5	18.2	14.6	
Leukemia	223.5	205.5	216.4	220.5	239.7	
Liver Cancer	62.7	67.7	74.2	69.0	72.6	
Lung Cancer	242.9	226.9	247.6	246.7	281.9	
Melanoma	108.0	97.7	110.8	103.7	102.3	
Multiple Myeloma	30.3	32.3	41.5	45.2	48.5	
Non Hodgkin's Lymphoma	114.1	113.0	122.6	131.3	122.4	
Ovarian Cancer	95.1	96.9	100.0	110.1	112.3	
Pancreatic Cancer	74.2	73.3	87.3	89.6	97.1	
Prostate Cancer	293.2	296.1	285.4	285.1	300.5	
Stomach Cancer	11.5	12.0	12.4	15.4	14.5	
Uterine Cancer	19.4	16.6	17.1	18.0	14.2	

FY 2009 and 2010 NCI American Recovery and Reinvestment Act (Recovery Act) Spending by Mech					
(dollars in thousands)					
		009		2010	
	No.	Amount	No.	Amount	
Research Project Grants:					
Noncompeting	-	-	479	\$183,403	
Admin Supplements	487	\$141,375	(12)	6,586	
Competing	543	230,825	3	5,392	
Subtotal, RPG	1030	372,200	482	195,381	
SBIR/STTR	1	6,906	-	47	
Total, RPG	1031	379,106	482	195,428	
Cancer Centers	13	72,212	-	9,007	
Specialized Cancer Centers (U54)	6	18,040	4	7,698	
SPOREs	2	6,831	-	-	
Total: Centers, Spec Ctrs, & SPOREs	21	97,083	4	16,705	
Research Career Program	-	11,360	-	-67	
Cancer Education	1	1,292	-	-	
Clinical Cooperative Groups	-	19,821	-	4,598	
Other Grants	1	11,201	-	9,998	
Subtotal, Other	2	43,674	0	14,529	
Total, Research Grants	1054	519,863	486	266,662	
National Research Service Awards	10	1,109	-	-	
R&D Contracts	-	318,458	78	175,284	
Intramural Research	-	143	-	5,490	
Research Management & Support	-	6,023	-	3,484	
Total, NCI	1064	845,596	564	410,920	
Total Recover Act Amount 1,256,516					

NCI received \$1.257 billion in American Recovery and Reinvestment Act (Recovery Act) funds to be awarded over a two year period -- FY 2009 and FY 2010. These Recovery Act funds are an investment in building a strong foundation for a 21st century economy, including sustaining and building the American workforce. The following programs of note are receiving Recovery Act funds through NCI:

- Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW) Funding 37 promising clinical trials of molecularly-targeted therapies to speed the delivery of personalized cancer treatments to patients.
- Cancer Centers Programs 62 NCI designated Cancer Centers across the country received \$63 million in Recovery Act funding to supplement Cancer Center Support Grants.
- Personalized Cancer Care / Drug Development Platform Enabling drug development that begins with the discovery of genetic changes and ends with targeted cancer therapies.
 Programs that support this vision include:
 - The Cancer Genome Atlas (TCGA) is developing a comprehensive catalog of genomic changes found in adult cancers;
 - Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is mapping the genetic changes associated with childhood cancers;
 - The Cancer Human Biobank (caHUB) leads quality biospecimen collection and management The NCI Community Cancer Centers Program (NCCCP) involves patients around the
 - country who provide data and volunteer for clinical trials.
- Physical Sciences in Oncology Centers Exploring perspectives from the physical sciences to enhance our understanding of cancer biology.

National Cancer Institute

Director's Biography Harold Varmus, M.D.

Harold Varmus became Director of the National Cancer Institute on July 12, 2010.

Dr. Varmus, a co-recipient of the Nobel Prize for studies of the genetic basis of cancer, served 10 years as President of Memorial Sloan-Kettering Cancer Center, following six years as Director of the National Institutes of Health. He is a member of the U.S. National Academy of Sciences and the Institute of Medicine and is involved in initiatives to promote science in developing countries, including the Global Science Corps. The author of over 350 scientific papers and five books, including a recent memoir titled The Art and Politics of Science, he was a co-chair of President Obama's Council of Advisors on Science and Technology, was a co-founder and Chairman of the Board of the Public Library of Science, and chaired the Scientific Board of the Gates Foundation Grand Challenges in Global Health. In 2001, he received the National Medal of Science.

Former Directors of the National Cancer Institute

John E. Niederhuber, M.D.

June 2006 – September 2006 (Acting) September 2006 – July 2010

John E. Niederhuber, M.D., became Director of the National Cancer Institute (NCI), one of the National Institutes of Health, in September 2006. He joined NCI in a full-time capacity in September 2005, as Deputy Director for Translational and Clinical Sciences, and within a few weeks was asked to serve as Chief Operating Officer. He officially became NCI's Acting Director in June 2006. Dr. Niederhuber has also served as the Chair of the National Cancer Advisory Board, as an external NCI advisor and grant reviewer, and as a laboratory investigator supported by NCI and the NIH.

Andrew C. von Eschenbach, M.D. January 2002 - September 2005

Andrew C. von Eschenbach, M.D. became the 12th NCI in January 2002. He previously directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.

Richard D. Klausner, M.D. August 1995 - September 2001

Dr. Klausner was appointed as the Director of the NCI on August 1. 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development.

Samuel Broder, M.D.

December 1988 - March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program.

Vincent T. DeVita, Jr., M.D. January 1980 – June 1980 (Acting) July 1980 - August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

Arthur Canfield Upton, M.D. July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

Frank Joseph Rauscher, Jr., Ph.D. May 1972 - October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

Carl Gwin Baker, M.D. November 1969 – July 1970 (Acting)

July 1970 - April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

Kenneth Milo Endicott, M.D. July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

John Roderick Heller, M.D. May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Former Directors of the National Cancer Institute (continued)

Leonard Andrew Scheele, M.D.	Dr. Scheele served in various capacities during his tenure with PHS
July 1947 – April 1948	prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

August 1943 – July 1947 was appointed Director of the Institute in 1943.	Roscoe Roy Spencer, M.D. August 1943 – July 1947	Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.
--	---	--

Carl Voegtlin, Ph.D.	Dr. Voegtlin served as Professor of Pharmacology and Chief of the
January 1938 – July 1943	Division of Pharmacy at the Hygienic Laboratory prior to becoming the
	first Director of NCI in 1938.

National Cancer Advisory Board (NCAB)

Membership and Term

Chairperson

2012 Bruce A. Chabner, M.D.
 Massachusetts General Hospital Cancer Center
 Massachusetts General Hospital
 Boston, MA 02114

Chairperson (Retired September 2010)

2010 Carolyn D. Runowicz, M.D.
The Carol and Ray Neag Comprehensive
Cancer Center
University of Connecticut Health Center
Farmington, CT 06030

2012 Anthony Atala, M.D.
Wake Forest Institute for Regenerative Medicine
Department of Urology
Wake Forest University School of Medicine
Winston-Salem, NC 27157

2014 Victoria L. Champion, D.N.S. Center for Research & Scholarship Indiana University School of Nursing Indianapolis, IN 46202

2012 Donald S. Coffey, Ph.D. Departments of Urology/Oncology/Pathology Pharmacology and Molecular Science Johns Hopkins University School of Medicine Baltimore, MD 21287

2016 Marcia R. Cruz-Correa, M.D., Ph.D.* University of Puerto Rico Basic and Translational Science Director University of Puerto Rico Comprehensive Cancer Center San Juan, Puerto Rico

2016 Kevin J. Cullen, M.D.* Marlene and Stewart Greenebaum Cancer Center University of Maryland Baltimore, MD

2010 Lloyd K. Everson, M.D. US Oncology Incorporated Houston, TX 77060

2010 Kathryn Giusti, M.B.A. Multiple Myeloma Research Foundation, Inc. Multiple Myeloma Research Consortium Norwalk, CT 06851

2014 William H. Goodwin, Jr. CCA Industries, Inc. Richmond, VA 23219 2014 Waun Ki Hong, M.D. Department of Thoracic/Head & Neck Medical Oncology The University of Texas M.D. Anderson Cancer Center Houston, TX 77030

2012 Mr. Robert A. Ingram General Partner Hatteras Venture Partners Durham, NC 27701

2012 Judith S. Kaur, M.D.
 Native American Programs
 Mayo Comprehensive Cancer Center
 Department of Medical Oncology
 Mayo Clinic
 Rochester, MN 55905

2010 Mr. David H. Koch Koch Industries New York, NY 10021

2014 Mary Vaughan Lester Board of Directors University of California San Francisco Foundation Los Angeles, CA 99024

2010 Diana M. Lopez, Ph.D. Department of Microbiology and Immunology University of Miami Miller School of Medicine Miami, FL 33136

2014 H. Kim Lyerly, M.D.

Duke Comprehensive Cancer Center

Duke University Medical Center

Durham, NC 27705

2012 Karen Dow Meneses, Ph.D.School of NursingUniversity of Alabama at BirminghamBirmingham, AL 35294

2016 Olufunmilayo I. Olopade, M.D., F.A.C.P.* Center for Clinical Cancer Genetics University of Chicago Pritzker School of Medicine Chicago, IL

* Newly appointed member pending personnel

National Cancer Advisory Board (Continued)

2014 Jennifer A. Pietenpol, Ph.D. Vanderbilt-Ingram Cancer Center B.F. Byrd, Jr. Professor of Oncology Professor of Biochemistry Vanderbilt University Medical Center Nashville, TN 37232

2016 Jonathan M. Samet, M.D., M.S.* Keck School of Medicine Institute for Global Health University of Southern California Los Angeles, CA

Ex Officio Members

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. Director National Institute of Environmental Health Sciences and The National Technology Program National Institutes of Health Research Triangle Park, NC

Francis S. Collins, M.D., Ph.D. Director National Institutes of Health Bethesda, MD

Margaret A. Hamburg, M.D. Commissioner Food and Drug Administration Silver Spring, MD

John P. Holdren, Ph.D.
Science Advisor to the President
Director
Office of Science and Technology Policy
Executive Office of the President
Washington, DC

John Howard, M.D., M.P.H., J.D., LL.M. Director

National Institute for Occupational Safety and Health Washington, DC

Lisa Jackson, M.S. Administrator Environmental Protection Agency Washington, DC 2016 William R. Sellers, M.D.* Novartis Institutes for BioMedical Research, Inc. Cambridge, MA

2010 Daniel D. Von Hoff, M.D., F.A.C.P. Translational Drug Development Division Translational Genomics Research Institute University of Arizona Department of Medicine Phoenix, AZ 85004

Executive Secretary Paulette S. Gray, Ph.D.

Committee Management Officer
Ms. Claire L. Harris

The Honorable Dr. Michael J. Kussman Under Secretary for Health Veterans Health Administration Department of Veterans Affairs Washington, DC

Anna Palmisano, Ph.D.
Associate Director, Office of Biological and
Environmental Research
Department of Energy
Washington, DC

The Honorable Kathleen Sebelius, M.P.A. Secretary Department of Health and Human Services Washington, DC

The Honorable Hilda L. Solis Secretary Department of Labor Washington, DC

George P. Taylor, Jr., M.D., M.P.H. Performing the Duties of the Assistant Secretary of Defense for Health Affairs The Pentagon Washington, DC

Inez Tenenbaum, M.Ed. Chairman Consumer Product Safety Commission Bethesda, MD

* Newly appointed member pending personnel

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Michael A. Babich, Ph.D.

Directorate for Epidemiology and Health Sciences

Consumer Product Safety Commission

Bethesda, MD

(Ms. Inez Tenenbaum- CPSC)

Patricia Bray, M.D., M.P.H.

Acting Director, Office of Occupational Medicine

OSHA / Department of Labor

Washington, DC 20210

(The Honorable Hilda L. Solis-DOL)

Michael Kelley, M.D., F.A.C.P.

National Program Director for Oncology

Veterans Health Administration

Department of Veterans Affairs

Durham, NC 27705

(The Honorable Dr. Michael J. Kussman)

Steven Kleeberger, Ph.D.

Acting Deputy Director

National Institute of Environmental Health Sciences

National Institutes of Health

Research Triangle Park, NC

(Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.- NIEHS)

Richard Pazdur, M.D.

Division Director

Division of Oncology Drugs

Food and Drug Administration

Rockville, MD

(Margaret A. Hamburg, M.D. - FDA)

John F. Potter, M.D.

Director

United States Military Cancer Institute

Walter Reed Army Medical Center

Washington, DC

(George P. Taylor, Jr., M.D., M.P.H.)

Note: Bold print represents Ex Officio Members

R. Julian Preston, Ph.D. Associate Director for Health Environmental Protection Agency Research Triangle Park, NC (Lisa Jackson, M.S. - EPA)

Michael Stebbins, Ph.D.

Assistant Director, Biotechnology

Office of Science and Technology Policy

Executive Office of the President

Washington, DC

(John P. Holdren, Ph.D. -OSTP)

Marie H. Sweeney, Ph.D., M.P.H.

Chief

Surveillance Branch

Division of Surveillance

Hazard Evaluations & Field Studies.

National Institute for Occupational Safety

and Health

Cincinnati. Ohio

(John Howard, M.D., M.P.H., J.D., LL.M.- NIOSH)

Lawrence A. Tabak, D.D.S., Ph.D.

Principal Deputy Director

National Institutes of Health

Bethesda, MD

(Francis S. Collins, M.D., Ph.D.)

Sharlene Weatherwax, Ph.D.

Director

Biological Systems Sciences Division

Office of Biological and Environmental Research

Office of Science

U.S. Department of Energy

Washington, DC

(Anna Palmisano, Ph.D. - DOE)

National Cancer Advisory Board (Continued)

NCAB Subcommittee Assignments

Subcommittee on Activities and Agenda

Dr. Bruce Chabner - Chair

Dr. Carolyn Runowicz - Chair (Retired 2010)

Dr. Victoria Champion

Dr. Diana Lopez (Retired 2010)

Dr. Karen Meneses

Executive Secretary: Dr. Paulette Gray (301) 496-5147

Subcommittee on Cancer Centers

Kim Lyerly - Chair

Dr. Bruce Chabner

Dr. Victoria Champion

Dr. Lloyd Everson (Retired 2010)

Mr. William Goodwin

Dr. Judith Kaur

Dr. Karen Meneses

Dr. Jennifer Pietenpol

Executive Secretary: Dr. Linda Weiss

(301) 496-8531

Subcommittee on Clinical Investigations

Dr. Waun Ki Hong - Chair

Dr. Anthony Atala

Dr. Lloyd Everson (Retired 2010)

Ms. Kathryn Giusti (Retired 2010)

Mr. William Goodwin

Dr. Judith Kaur

Ms. Mary Lester

Dr. Kim Lyerly

Dr. Daniel Von Hoff (Retired 2010)

Executive Secretary: Dr. Jeff Abrams

(301) 496-2522

Subcommittee on Planning and Budget

Dr. Bruce Chabner - Chair

Mr. William Goodwin

Mr. David Koch (Retired 2010)

Dr. Diana Lopez (Retired 2010)

Dr. Kim Lyerly

Executive Secretary: Mr. Jim Dickens

(301) 496-5803

Subcommittee on Special Actions

Dr. Karen Meneses - Chair

Committee of the Whole

Executive Secretary: Dr. Paulette Gray

(301) 496-5147

Ad hoc Subcommittee on Biomedical Technology

Dr. Donald Coffey - Chair

Dr. Anthony Atala

Ms. Kathryn Giusti (Retired 2010)

Mr. David Koch (Retired 2010)

Ms. Mary Lester

Dr. Kim Lyerly

Dr. Jennifer Pietenpol

Executive Secretary: Dr. Carolyn Compton

(301) 496-1550

Ad hoc Subcommittee on Communications

Chair - TBN

Dr. Diana Lopez - (Chair Retired 2010)

Dr. Victoria Champion

Dr. Lloyd Everson Retired 2010)

Mr. Robert Ingram

Dr. Judith Kaur

Ms. Mary Lester

Dr. Kim Lyerly

Dr. Karen Meneses

Executive Secretary: Dr. Lenora Johnson

(301) 451-6879

Ad hoc Subcommittee on Experimental Therapeutics

Chair - TBN

Dr. Daniel Von Hoff - Chair (Retired 2010)

Dr. Bruce Chabner

Mr. William Goodwin

Dr. Waun Ki Hong

Dr. Kim Lyerly

Executive Secretary: Dr. Joseph Tomaszewski

(301) 496-6711

Ad Hoc Subcommittee on Global Cancer Research

Chair -TBN

Dr. Anthony Atala

Dr. Waun Ki Hong

Dr. Kim Lyerly

Executive Secretary: TBN

Board of Scientific Counselors

	Intramural P	rograms	
C	linical Sciences and	d Epidemiology	
Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Chair - Ethan Dmitrovsky, M.D.	2013		
Wadih Arap, M.D., Ph.D.	2011	David Poplack, M.D.	2014
Edgar Ben-Josef, M.D.	2014	Nancy Roach	2013
Bruce Blazar, M.D.	2012	Thomas Rohan, M.D., Ph.D.	2014
Tim Byers, M.D.	2015	Daniel Schaid, Ph.D.	2011
William Cance, M.D.	2011	Thomas Sellers, Ph.D.	2013
Susan Chang, M.D.	2013	Darryl Shibata, M.D.	2015
William Evans, Pharm.D.	2012	Robert Tigelaar, M.D.	2013
Jo Freudenheim, Ph.D.	2012	Walter Urba, M.D., Ph.D.	2013
Judy Garber, M.D.	2012	Elizabeth Ward, Ph.D.	2014
Marc Goodman, Ph.D.	2015	Cheryl Willman, M.D.	2015
Bernard Harlow, Ph.D.	2014		
Carl June, M.D.	2014		
Karen Kelly, M.D.	2015	Executive Secretary - Brian Wojcik	, Ph.D.
Alexandra Levine, M.D.	2015		
Augusto Ochoa, M.D.	2014		
	Basic Scie	ences	
Chair - Laurence Hurley Ph D	2011		

Chair - Laurence Hurley, Ph.D.	2011		
Cory Abate-Shen, Ph.D.	2011	Marcelo Kazanietz, Ph.D.	2015
Dafna Bar-Sagi, Ph.D.	2011	Jonathan Licht, M.D.	2014
Paul Bieniasz, Ph.D.	2014	Wendell Lim, Ph.D.	2011
John Cambier, Ph.D.	2015	A. Thomas Look, M.D.	2013
Selina Chen-Kiang, Ph.D.	2011	Ian Macara, Ph.D.	2014
Joan Conaway, Ph.D.	2015	Nita Maihle, Ph.D.	2012
Lawrence Corey, M.D.	2014	Lynn Matrisian, Ph.D.	2012
Norman Drinkwater, Ph.D.	2014	Suzanne Ostrand-Rosenberg, Ph.D.	2014
Nelson Fausto, M.D.	2012	Ann Marie Pendergast, Ph.D.	2012
Errol Friedberg, M.D.	2014	Thomas Poulos, Ph.D.	2015
Thomas Hamilton, Ph.D.	2011	James Prestegard, Ph.D.	2013
Daria Hazuda, Ph.D.	2015	Kenneth Rock, M.D.	2015
Eric Hunter, Ph.D.	2015	Ming You, M.D., Ph.D.	2011
Chris Ireland, Ph.D.	2013	Virginia Zakian, Ph.D.	2015
Marc Jenkins, Ph.D.	2013	Executive Secretary - Florence E. Farber, Ph	.D.

Board of Scientific Advisors

Extramural Programs

	=/((: 0(: : : 0: : 0(: :	109.4.110	
Chair - Richard L. Schilsky, M.D.	2011		
Paul M. Allen, Ph.D.	2011	Marc A. Kastner, Ph.D.	2012
Christine B. Ambrosone, Ph.D.	2012	Timothy J. Kinsella, M.D.	2012
Andrea Califano, Ph.D.	2013	Joshua LaBaer, M.D., Ph.D.	2014
Michael A. Caligiuri, M.D.	2012	Mr. Donald Listwin	2014
Arul M. Chinnaiyan, M.D., Ph.D.	2015	Christopher J. Logothetis, M.D.	2011
Curt I. Civin, M.D.	2012	Maria E. Martinez, Ph.D., M.P.H.	2015
Susan J. Curry, Ph.D.	2010	Kathleen H. Mooney, Ph.D., F.A.A.N., R.N.	2010
William S. Dalton, M.D., Ph.D.	2010	James L. Omel, M.D.	2012
Chi V. Dang, M.D., Ph.D.	2014	Edith A. Perez, M.D.	2011
Ronald A. DePinho, M.D.	2015	Robert D. Schreiber, Ph.D.	2010
Robert B. Diasio, M.D.	2013	Stuart L. Schreiber, Ph.D.	2012
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S.	2014	Bruce W. Stillman, Ph.D.	2012
Betty Ferrell, Ph.D., RN, F.A.A.N.	2015	Victor J. Strecher, Ph.D. MPH	2012
Kathleen M. Foley, M.D.	2013	Louise C. Strong, M.D.	2013
Sanjiv S. Gambhir, M.D., Ph.D.	2012	Frank M. Torti, M.D., M.P.H.	2014
Todd R. Golub, M.D.	2011	Jean Y. Wang, Ph.D.	2011
Joe W. Gray, Ph.D.	2013	Irving L. Weissman, M.D.	2012
James R. Heath, Ph.D.	2010	James K. Willson, M.D.	2011
Mary J. C. Hendrix, Ph.D.	2012	Executive Secretary - Paulette S. Gray, Ph.D.	

President's Cancer Panel

LaSalle D. Leffall, Jr. M.D., F.A.C.S. 2011

Charles R. Drew Professor of Surgery Howard University Hospital

2041 Georgia Avenue, NW

Suite 4000

Washington, DC 20060

Member

(Vacant)

Margaret L. Kripke, Ph.D. 2011

Vivian L. Smith Chair and Professor Emerita

University of Texas

M.D. Anderson Cancer Center

Unit 113

1515 Holcombe Boulevard

Houston, TX 77030

Abby B. Sandler, Ph.D.

Executive Secretary

Chief, NCI Institute Review Office

6116 Executive Blvd. Suite 220, MSC 8349 Bethesda, MD 20892-8349

Scientific Program Leaders (SPL) Members

2011

Harold Varmus, M.D.

Director

Kenneth H. Buetow, Ph.D.

Director, Center for Biomedical Informatics and Information Technology

Robert T. Croyle, Ph.D.

Director, Division of Cancer Control and

Population Sciences

John Czajkowski

Deputy Director for Management

James H. Doroshow, M.D.

Director, Division of Cancer Treatment

and Diagnosis

Joseph F. Fraumeni, Jr., M.D.

Director, Division of Cancer Epidemiology and

Genetics

Paulette S. Gray, Ph.D.

Director, Division of Extramural Activities

Peter Greenwald, M.D., Dr.Ph

Director, Division of Cancer Prevention

Lee Helman, M.D.

Scientific Director for Clinical Research, CCR

Douglas Lowy, M.D.

Deputy Director

Alan S. Rabson, M.D.

Deputy Director

Dinah S. Singer, Ph.D.

Director, Division of Cancer Biology

Sanya A. Springfield, Ph.D.

Director, Center to Reduce

Cancer Health Disparities

Michael Weingarten

Director, SBIR Development Center

Linda Weiss, Ph.D.

Director, Cancer Centers

Jonathan Wiest, Ph.D.

Director, Center for Cancer Training

Robert H. Wiltrout, Ph.D.

Director, Center for Cancer Research

Robert Yarchoan, M.D.

Director, Office of HIV & AIDS Malignancy

Joy Wiszneauckas, M.B.A

Executive Secretary

Clinical Trials and Translational Research Advisory Committee (CTAC)

Membership and Term

Chair

Harold E. Varmus, M.D.

Director

National Cancer Institute National Institutes of Health

Bethesda, MD

2010 James L. Abbruzzese, M.D.

Chairman

Department of Gastrointestinal Medical Oncology The University of Texas M.D. Anderson Cancer Center

Houston, TX

2010 Peter C. Adamson, M.D.

Professor

Pediatrics and Pharmacology

Chief

Clinical Pharmacology and Therapeutics

The Children's Hospital of Philadelphia

The University of Pennsylvania

Philadelphia, PA

2011 Deborah W. Bruner, Ph.D., R.N.

Professor of Nursing

Director

Clinical Trials Recruitment, Retention, and Outreach

Core Facility

Abramson Cancer Center

The University of Pennsylvania

Philadelphia, PA

2012 Curt Civin, M.D. (BSA)

Associate Dean of Research

Professor of Pediatrics

Director

Center for Stem Cell Biology and Regenerative Medicine

University of Maryland School of Medicine

Baltimore, MD

2012 Kenneth H. Cowan, M.D., Ph.D.

Director

Eppley Institute for Cancer Research

University of Nebraska Medical Center

Omaha, NE

2011 Everett Dodson (DCLG)

Community Health Educator

Lombardi Comprehensive Cancer Center

Washington, D.C.

2013 Olivera J. Finn, Ph.D.

Professor and Chair

University of Pittsburgh School of Medicine

Pittsburgh, PA

2010 Stephen S. Grubbs, M.D.

Chief of Oncology

Medical Oncology Hematology Consultants

Newark, DE

2011 Sandra J. Horning, M.D

Senior VP, Global Head

Clinical Development Hematology/Oncology

Genentech, Inc.

South San Francisco, CA

2010 K. Gabriel Leung, M.S.

Pharmaceutical Business

OSI Pharmaceuticals

Melville, NY

2013 Scott M. Lippman, M.D.

Professor and Chair

Department of Thoracic/Head and Neck

Medical Oncology

The University of Texas M.D. Anderson

Cancer Center

Houston, TX

2011 Nancy P. Mendenhall, M.D.

Professor

Department of Radiation Oncology

College of Medicine

Medical Director

Proton Therapy Institute

University of Florida

Gainesville, FL

2010 David R. Parkinson, M.D.

President and CEO

Nodality, Inc.

South San Francisco, CA

2011 Edith A. Perez, M.D. (BSA)

Deputy Director

Mayo Clinic Comprehensive Cancer Center

Serene M. and Francese C. Durling

Professor of Medicine

Division of Hematology/Oncology

Chair, Breast Disease Oriented Group

Mayo Clinic

Jacksonville, FL

2013 Nancy Roach (BSC)

Consumer Advocate

C3: Colorectal Cancer Coalition

Hood River, OR

Clinical Trials and Translational Research Advisory Committee (Continued)

Membership and Term

2011 Daniel J. Sargent, Ph.D.

Director

Cancer Center Statistics

Professor

Division of Biostatistics

Mayo Clinic Comprehensive Cancer Center

Rochester, MN

2011 Richard L. Schilsky, M.D. (BSA)

Professor of Medicine

Associate Dean for Clinical Research

Biological Sciencese Division

University of Chicago

Pritzker School of Medicine

Chicago, IL

2013 Mitchell D. Schnall, M.D., Ph.D.

Matthew J. Wilson Professor of Radiology

Magnetic Resonance Imaging Section

Department of Radiology

The University of Pennsylvania School of Medicine

Philadelphia, PA

Ex Officio Members

James H. Doroshow, M.D.

Director

Division of Cancer Treatment and Diagnosis

National Cancer Institute

National Institutes of Health

Bethesda, MD

Paulette Gray, Ph.D.

Director

Division of Extramural Activities

National Cancer Institute

National Institutes of Health

Bethesda, MD

Rosemarie Hakim, Ph.D., M.S.

Epidemiologist

Centers for Medicare and Medicaid Services

Baltimore, MD

Lee Helman, M.D.

Chief

Pediatric Oncology Branch

Scientific Director for Clinical Research

Center for Cancer Research

National Cancer Institute

National Institutes of Health

Bethesda, MD

2010 Joel E. Tepper, M.D.

Professor and Chair

Department of Radiation Oncology

University of North Carolina School of

Medicine

Chapel Hill, NC

2011 James L. Wade, III, M.D.

Director of Medical Oncology

Department of Clinical Research

Medical Director

Decatur Memorial Hospital Cancer Care

Institute

Decatur Memorial Hospital

Decatur, IL

Executive Secretary

Sheila A. Prindiville, M.D., MPH

Michael J. Kelley, M.D., FACP

National Program Director for Oncology

Veterans Health Administration

Department of Veterans Affairs

Washington, DC

Richard Pazdur, M.D., FACP

Director

Division of Oncology Drug Products U.S. Food and Drug Administration

Rockville, MD

John F. Potter, M.D.

Director

United States Military Cancer Institute

Walter Reed Army Medical Center

Washington, DC

Alan Rabson, M.D.

Deputy Director

National Cancer Institute

National Institutes of Health

Bethesda, MD

Clinical Trials and Translational Research Advisory Committee (Continued)

CTAC Subcommittee

Ad hoc Coordination Subcommittee

James L. Abbruzzese, M.D. (Chair)

Chairman

Department of Gastrointestinal Medical Oncology The University of Texas M.D. Anderson Cancer Center

Houston, TX

Laurence H. Baker, D.O. (Ad hoc)

Chairman

Southwest Oncology Group

Professor of Medicine

University of Michigan

Ann Arbor, MI

Charles Erlichman, M.D. (Ad hoc)

Chairman

Department of Oncology

Deputy Director for Clinical Affairs

Mayo Clinic Cancer Center

Rochester, MN

Richard L. Schilsky, M.D.

Professor of Medicine

Associate Dean of Clinical Research

Biological Sciences Division

University of Chicago

Pritzker School of Medicine

Chicago, IL

James H. Doroshow, M.D. (Ad hoc)

Director

Division of Cancer Treatment and Diagnosis

National Cancer Institute

National Institutes of Health

Bethesda, MD

Sherwood Githens, Ph.D. (Ad hoc)

Scientific Review Officer

Special Reviewe and Logistics Branch

Division of Extramural Activities

National Cancer Institute

National Institutes of Health

Bethesda, MD

Paulette Gray, Ph.D. (Ad hoc)

Director

Division of Extramural Activities

National Cancer Institute

National Institutes of Health

Bethesda, MD

Sheila A. Prindiville, M.D., MPH

Director

Coordinating Center for Clinical Trials

Office of the Director

National Cancer Institute

National Institutes of Health Bethesda, MD

Executive Secretary


301-451-5048


NCI Director's Consumer Liaison Group


Ms. Gwen Darien, Chair Samuel Waxman Cancer Foundation	2012	Dr. Deborah Morosini Lung Cancer Alliance	2012
Mr. Everett E. Dodson, Vice Chair Georgetown University Lombardi Comprehensive Cancer Center	2011	Ms. Phyllis Pettit Nassi University of Utah Huntsman Cancer Institute	2012
Dr. Jeff Allen Friends of Cancer Research	2013	Mr. Jon Retzlaff American Association for Cancer Research	2014
Ms. Susan Braun Commonweal	2013	Ms. Wendy Selig Melanoma Research Alliance	2012
Ms. Marie Dahlstrom De La Mano Frente Al Cancer: Latino Cancer Coalition	2011	Mr. Josh Sommer The Chordoma Foundation	2014
Ms. Joyce Wilcox Graff VHL Family Alliance	2011	Ms. Arlene Wahwasuck Four Tribes Women's Wellness Coalition	2011
Ms. Cheryl Jernigan Susan G. Komen for the Cure	2012	Mr. Max Wallace Accelerate Brain Cancer Cure	2013
Dr. Michelle McMurry Food and Drug Administration	2014		

Mr. Ben Carollo, MPA
Executive Secretary
Director, Office of Advocacy Relations
National Cancer Institute
31 Center Drive, Room 10A28
Bethesda, MD 20892-2580

National Cancer Institute







Center for Biomedical Informatics and Information Technology

Director Dr. Ken Buetow 301-435-1520

Deputy Director Dr. George Komatsoulis 301-451-2881

Infrastructure Branch

Chief Mr. Eric Williams 301-594-0764

Informatics Operations Branch

Chief Ms. Caterina Lasome 301-594-1604

Information Technology Support Branch

Chief Vacant

Resource Management Branch

Acting Chief Dr. George Komatsoulis 301-451-2881

Office of Science Planning and Assessment

Acting Director Dr. Margaret Ames 301-402-7519

Acting Deputy Director Dr. Lisa Stevens 301-435-3861

Women's Health

Officer Ms. Karen Parker 301-451-9462

Program Assessment Branch


Chief Dr. James Corrigan 301-435-3856

Science Planning Branch

Chief Dr. Lisa Stevens 301-435-3861

Program Implementation Branch

Chief Ms. Susanne Strickland 301-496-5516



Center for Strategic Scientific Initiatives

Acting Director Dr. Doug Lowy 301-435-0191

Deputy Director Dr. Jerry Lee 301-496-1045

Office of Cancer Genomics

Director Dr. Daniela S. Gerhard 301-451-8027

Office of Biorepositories and Biospecimen Research

Director Dr. Carolyn C. Compton 301-594-2212

Knowledge Management and Special Projects Branch

Chief Ms. Lisa Krueger 301-451-5115

The Cancer Genome Atlas Program Office

Director Vacant 301-435-0191

Office of Cancer Nanotechnology Research

Director Dr. Piotr Grodzinski 301-594-4177

Office of Cancer Clinical Proteomics Research

Director Dr. Henry Rodriguez 301-594-6345

Office of Physical Sciences-Oncology

Acting Director Dr. Jerry Lee 301-496-1045

Center for Global Cancer Health Research

Director Vacant 301-496-1045

Office of International Affairs

Director Dr. Joe Harford 301-496-5534

Office of Latin American Cancer Program Development

Director Dr. Jorge Gomez 301-435-9040

Center to Reduce Cancer Health Disparities

Director Dr. Sanya Springfield 301-496-8589

Deputy Director Dr. Deborah Duran 301-496-8589

Disparities Research Branch

Chief Dr. Ken Chu 301-435-9213


Diversity Training Branch

Chief Dr. Alexis Bakos 301-435-9044

Center for Cancer Research Office of the Director

Director
Dr. Robert Wiltrout
301-496-4345

Dr. Lee Helman Scientific Director for Clinical Research 301-496-4346



Dr. Kathleen Kelly 301-435-4651

Laboratory of Comparative

Carcinogenesis

Chief

Dr. Larry Keefer

301-846-1467

Dr. Kenneth Buetow

301-435-8953

Clinical Component Deputy

Dr. Mark Udey

301-496-2481

Dr. R. Andrew Byrd

301-846-1407

Laboratory of Molecular

Immunoregulation

Chief

Dr. Joost Oppenheim

301-846-1551

Division of Cancer Biology

Office of the Director

Director

Dr. Dinah S. Singer 301-496-8636

Deputy Director Dr. Dan Gallahan

301-496-8636

Associate Director

Dr. Cheryl Marks

301-594-8778

Associate Director

Dr. Suresh Mohla

301-435-1878

Cancer Etiology Branch

Chief

Dr. Don Blair 301-496-9740

Cancer Immunology and Hematology Branch

Chief

Dr. R. Allan Mufson 301-496-7815

Cancer Cell Biology Branch

Chief

Dr. Barbara Spalholz 301-496-7028

Tumor Biology and Metastasis Branch

Chief

Dr. Suresh Mohla 301-435-1878

DNA and Chromosome Aberrations Branch

Chief Dr. Judith Mietz 301-496-9326

Structural Biology and Molecular Applications Branch

Chief

Dr. Jennifer Couch 301-435-5226

Division of Cancer Epidemiology and Genetics

Office of the Director

Director

Dr. Joseph F. Fraumeni, Jr. 301-496-1611

Deputy Director Dr. Shelia H. Zahm 301-496-8157

Office of Communications and Special Initiatives

301-496-6271

Chief
Ms. Catherine B. McClave

Office of Division Operations and Analysis

Chief

Ms. Marianne K. Henderson 301-496-8672

Office of Education

Chief

Dr. Jackie A. Lavigne 301-451-4435

Epidemiology and Biostatistics Program

Director

Dr. Robert N. Hoover 301-496-3004

Human Genetics

Program Director

Dr. Margaret A. Tucker 301-496-4375

Biostatistics Branch

Chief

Dr. Nilanjan Chatterjee 301-402-7933

Hormonal and Reproductive Epidemiology Branch

Chief Dr. Louise A. Brinton 301-496-1691

Genetic Epidemiology Branch Chief

Dr. Margaret A. Tucker 301-496-4375

Clinical Genetics Branch

Chief Dr. Mark H. Greene 301-594-7642

Nutritional Epidemiology Branch

Chief Vacant 301-496-3004

Occupational and Environmental Epidemiology Branch Chief

Dr. Debra T. Silverman 301-435-4716

NCI Core Genotyping Facility

Director Dr. Stephen J. Chanock 301-435-7559

Laboratory of Translational Genomics

Chief

Dr. Stephen J. Chanock 301-435-7559

Radiation Epidemiology Branch

Chief Dr. Martha S. Linet 301-496-6600

Infections and Immunoepidemiology Branch

Chief Dr. Allan Hildesheim 301-435-3984

Division of Cancer Prevention

Office of the Director

Acting Director Dr. Lori Minasian 301-496-8541

Acting Deputy Director Dr. Leslie G. Ford 301-496-0265

Associate Director for Clinical Research Dr. Leslie G. Ford 301-496-0265

Breast & Gynecologic Cancer Research Group

Acting Chief
Dr. Diane Solomon
301-496-8526

Prostate & Urologic Cancer Research Group

Chief Dr. Howard Parnes 301-594-0920

Lung & Upper Aerodigestive Cancer Research Group

Chief Dr. Eva Szabo 301-435-1595

Gastrointestinal & Other Cancer Research Group

Chief Dr. Asad Umar 301-594-2684

Chemopreventive Agent Development Research Group

Acting Chief Dr. Vernon Steele 301-496-8563

Community Oncology and Prevention Trials Research Group

Chief Dr. Lori M. Minasian 301-496-8541

Nutritional Science Research Group

Chief Dr. John A. Milner 301-496-8573

Basic Prevention Science Research Group

Acting Chief
Dr. Peter Greenwald
301-496-6616

Cancer Biomarkers Research Group Chief

Dr. Sudhir Srivastava 301-435-1594

Early Detection Research Group

Chief Dr. Christine Berg 301-496-8544

Biometry Research Group Chief

Dr. Phillip C. Prorok 301-496-8556

Division of Cancer Control and Population Sciences

Deputy Director for Dissemination and Implementation Science

Dr. Russell Glasgow 301-435-4912

Office of the Director

Director Dr. Robert Croyle 301-594-6776

Deputy Director Dr. Deborah Winn 301-594-9499

Office of Cancer Survivorship

Director Dr. Julia H. Rowland 301-402-2746

Epidemiology and Genetics Research Program

Acting Associate Director Dr. Deborah Winn 301-594-9499

Methods and Technologies Branch

Chief Dr. Mukesh Verma 301-594-7344

Modifiable Risk Factors Branch

Chief Dr. Britt Reid 301-435-4914

Host Susceptibility Factors Branch

Chief Dr. Elizabeth Gillanders 301-594-5868

Clinical and Translational Epidemiology Branch Chief

Dr. Andrew Freedman 301-435-6819

Behavioral Research Program

Associate Director Dr. William Klein 301-435-6816

Applied Cancer Screening Research Branch

Acting Chief Dr. Stephen Taplin 301-402-1483

Basic and Biobehavioral Research Branch

Chief Dr. Paige Green McDonald 301-435-5037

Health Communication and Informatics Research Branch

Chief Dr. Bradford Hesse 301-594-9904

Health Promotion Research Branch

Chief Dr. Linda Nebeling 301-435-2841

Tobacco Control Research Branch

Chief Dr. Cathy Backinger 301-435-8638

Applied Research Program

Associate Director Dr. Rachel Ballard-Barbash 301-496-8500

Health Services and Economics Branch

Chief Dr. Martin Brown 301-496-5716

Outcomes Research Branch

Chief Dr. Steven Clauser 301-451-4402

Risk Factor Monitoring and Methods Branch

Chief Dr. Susan Krebs-Smith 301-496-4766

Surveillance Research Program

Associate Director Dr. Brenda K. Edwards 301-496-8506

Surveillance Systems Branch

Chief Dr. David Stinchcomb 301-594-7251

Data Analysis and Interpretation Branch

Acting Chief Dr. Kathleen Cronin 301-435-2792

Data Modeling Branch

Acting Chief Dr. Angela Mariotto 301-435-4923

Statistical Methodology and Applications Branch

Chief Dr. Eric Feuer 301-496-5029

Biometrics Research Branch

Chief Dr. Richard Simon 301-496-0975

Office of Cancer Complementary and **Alternative Medicine**

Associate Director Dr. Jeffrey White 301-435-7980

Division of Cancer Treatment and Diagnosis

Office of the Director

Director Dr. James H. Doroshow 301-496-4291

Deputy Director Dr. Joseph Tomaszewski 301-496-6711

Radiation Research Program

Associate Director Dr. C. Norman Coleman 301-496-6111

Radiotherapy **Development Branch**

Acting Chief Dr. Bhadrasain Vikram 301-496-6111

Molecular Radiation Therapeutics Branch

Chief Dr. Stephen S. Yoo 301-496-3080

Clinical Radiation Oncology Branch Chief

Dr. Bhadrasain Vikram 301-496-6111

Cancer Therapy Evaluation Program

Associate Director Dr. Jeffrey Abrams 301-496-6138

Investigational **Drug Branch**

Chief Dr. James Zwiebel 301-496-1196

Clinical Investigations Branch

Chief Dr. Margaret Mooney 301-496-2522

Pharmaceutical **Management Branch**

Chief Mr. Charles Hall 301-496-5725

Regulatory Affairs Branch

Chief Dr. Jan Casadei 301-496-7912

Clinical Trials Monitoring Branch

Acting Chief Mr. Gary Smith 301-402-5147

Clinical Grants and **Contracts Branch**

Chief Dr. Rov Wu 301-496-8866

Clinical Trials Operations and Informatics Branch

Chief Mr. Steven Friedman 301-435-9183

Developmental **Therapeutics Program**

Associate Director Dr. Jerry M. Collins 301-496-8720

Deputy Associate Director Dr. James Crowell 301-435-9152

Information Technology Branch Chief

Dr. Dan Zaharevitz 301-496-8747

Biological Testing Branch

Chief Dr. Melinda Hollingshead 301-846-5065

Biological Resources Branch

Chief Dr. Stephen Creekmore 301-846-1098

Toxicology and Pharmacology Branch

Chief Dr. Myrtle Davis 301-443-3404

Translational Research Program

Acting Associate Director Dr. Toby T. Hecht 301-435-9043

Screening Technologies Branch Chief

Dr. Robert Shoemaker 301-846-6845

Natural Products Branch

Chief Dr. David Newman 301-846-5387

Drug Synthesis and Chemistry Branch

Chief Dr. Joel Morris 301-435-9151

Grants & Contracts Operations Branch

Chief Dr. Mary Wolpert-DeFilippes 301-496-8783

Pharmaceutical Resources Branch

Chief Dr. Rao Vishnuvajjala 301-496-8780

Cancer Diagnosis Program

Associate Director Dr. Barbara Conley 301-435-9004

Diagnostics Evaluation Branch Chief

Dr. John Jessup 301-496-1591

Resources Development Branch Chief

Dr. Irina Lubensky 301-496-7147

Diagnostic Biomarkers and Technology Branch

Chief Vacant

Cancer Imaging Program

Acting Associate Director Dr. Paula Jacobs 301-435-9181

Deputy Associate Director Dr. Paula Jacobs 301-435-9181

Diagnostic Imaging Branch

Chief Dr. Lalitha Shankar 301-451-8491

Molecular Imaging Branch


Acting Chief Dr. Paula Jacobs 301-435-9181

Image-Guided Intervention Branch

Acting Chief Dr. Keyvan Farahani 301-451-2651

Imaging Technology **Development Branch**

Chief Dr. Laurence Clarke 301-435-9190



Links to Cancer Statistics

SOURCES:

2009 Report to the Nation on the Status of Cancer, 1975-2006

Annual Report to the Nation on the Status of Cancer, 1975-2006 provides information related to incidence, death rates, and trends in the United States. Contains a special feature on trends in lung cancer and related cancer control efforts. http://seer.cancer.gov/report_to_nation/

Fast Stats

Interactive tool providing tables, charts, and graphs with information related to incidence, mortality, survival and stage, prevalence, and lifetime risk (probability of developing or dying from cancer). http://seer.cancer.gov/faststats/

SEER Cancer Statistics Review, 1975-2007

Annually updated tables and graphs displaying cancer statistics by cancer site, year of diagnosis, age, race, sex, and geography, diagnosed between 1975 and 2007. Searchable cancer statistics related to incidence, mortality, survival, prevalence, and lifetime risk.

http://seer.cancer.gov/csr/1975 2007/index.html

Cancer Stat Fact Sheets

Collection of statistical summaries for a number of common cancer types, with information related to incidence, mortality, survival, stage, prevalence, and lifetime risk. http://seer.cancer.gov/statfacts/

REPORTS:

Costs of Cancer Care, 1963-2004

http://progressreport.cancer.gov/2007/doc_detail.asp?pid=1&did=2007&chid=75&coid=726&mid=

Relationship of Cancer to the Leading Causes of Death in the United States, 1975 and 2007 http://seer.cancer.gov/csr/1975 2007/results merged/topic lead cod.pdf

Estimated New Cancer Cases and Deaths for 2010

http://seer.cancer.gov/csr/1975 2007/results single/sect 01 table.01.pdf

Person-Years of Life Lost Due to Cancer and Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2007

http://seer.cancer.gov/csr/1975 2007/results merged/topic year lost.pdf

Incidence, Mortality, and Five-Year Relative Survival Rates by Cancer Site http://seer.cancer.gov/csr/1975 2007/results single/sect 01 table.04 2pgs.pdf

Annual Percent Change in Incidence and Mortality Rates, 1997-2007 http://seer.cancer.gov/csr/1975 2007/results merged/topic graph trends.pdf

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity http://seer.cancer.gov/csr/1975 2007/results merged/topic inc trends.pdf

Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity http://seer.cancer.gov/csr/1975 2007/results merged/topic mor trends.pdf

Prevalence of Cancer: Estimated Number of Persons Diagnosed with Cancer, 5- and 32-Year Limited Duration

http://seer.cancer.gov/csr/1975 2007/results merged/topic prevcounts.pdf

Fiscal Year 2010 Budget (Dollars in Thousands)

A. Actual Obligations Resulting From Appropriated Funds:

FY 2010 Appropriation	\$5,103,388
Supplemental Appropriations	\$0
Transfer under the HHS Secretary's transfer authority	-\$760
NIH Transfer for NIH Genes and Environmental Initiative	-4,459
Lapse	-22
Actual Obligations Subtotal	5,098,147


B. Reimbursable Obligations:

18,738 Reimbursements

C. Total NCI Obligations: \$5,116,885 *


^{*}EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

Prog Mgmt & Supp 8%



Budget Activity	Amount	Percent
Research:		
Cancer Causation	\$1,185,839	23.3%
Detection and Diagnosis Research	429,532	8.4%
Treatment Research	1,156,144	22.7%
Cancer Biology	783,019	15.4%
Subtotal Research	3,554,534	69.8%
Resource Development:		
Cancer Centers Support	568,424	11.1%
Research Manpower Development	179,346	3.5%
Buildings and Facilities	7,920	0.2%
Subtotal Resource Development	755,690	14.8%
Cancer Prevention and Control	364,107	7.1%
Program Management and Support	423,816	8.3%
*Total NCI	5,098,147	100.0%

^{*}EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)



Mechanism	Amount	Percent
Contracts:		_
R&D Contracts	613,762	15.7%
Buildings and Facilities	7,920	0.2%
Construction Contracts	0	0.0%
Subtotal Contracts	621,682	15.9%
Grants:		
Research Project Grants	2,168,058	55.4%
Cancer Centers/Specialized Centers/SPORES	611,133	15.6%
NRSA	67,564	1.7%
Other Research Grants	442,613	11.3%
Construction Grants	0	0.0%
Subtotal Grants	3,289,368	84.1%
Total Extramural Funds	3,911,050	100.0%
Total Intramural/RMS	1,187,097	
*Total NCI	\$5,098,147	

^{*}EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

NCI Obligations by Mechanism, Fiscal Year 2010 (Dollars in Thousands)


(Dollars III Tribusarius)				
		Number	Amount	% of Total
Research Project	Non-Competing	3,619	1,536,844	30.2%
Grants	Administrative Supplements	(254)	28,947	0.6%
Granio	Competing	1,253	516,598	10.1%
	Subtotal, without SBIR/STTR Grants	4,872	2,082,389	40.9%
	SBIR/STTR Grants	207	85,669	1.7%
	Subtotal, Research Project Grants	5,079	2,168,058	42.5%
Centers & SPOREs	Cancer Centers Grants-P20/P30	66	295,856	5.8%
	SPOREs-P50	63	133,810	2.6%
	Other P50s/P20s	19	38,765	0.8%
	Other Specialized Centers	102	142,702	2.8%
	Subtotal, Centers	250	611,133	12.0%
Other Research	Career Program		011,100	0.0%
other riescuron	Temin & Minority Mentored Awards-K01	77	10,823	0.2%
	Estab. Inv. Award-K05	21	3,134	0.1%
	Preventive Oncology-K07	97	13,278	0.3%
	Clinical Investigator-K08	83	12,408	0.2%
	Clinical Oncology-K12	18	12,922	0.2%
	Transitional Career Development-K22	30	4,963	0.1%
	Mentored Patient Oriented RCDA-K23	40	5,812	0.1%
	Mid-Career Invest. & Patient Orient. Res-K24	20	3,422	0.1%
	Mentored Quant. Res Career-K25	25	3,422	0.1%
	Inst. Curr. Award-K30	0	0,311	0.1%
		41		
	Pathway to Independence Awards-K99 Subtotal, Career Program	452	4,841 74,914	0.1% 1.5%
	Cancer Education Program-R25	91	35,444	0.7%
		131	254,487	5.0%
	Clinical Cooperative Groups-U10			
	Minority Biomedical Support-S06	0	466	0.0%
	Rsch Enhance-SC1 & Pilot Research - SC2	6	1,348	0.0%
	Continuing Education	6	685	0.0%
	Resource Grants-R24/U24	43	67,144	1.3%
	Explor Coop Agreement-U56	2	862	0.0%
	Global Infect. Disease Rsrch Training Prog - D43		5,599	0.1%
	Conference Grants-R13	87	1,664	0.0%
	Subtotal, Other Research Grants	827	442,613	8.7%
Subtotal, Research Gr		6,156	3,221,804	63.2%
NRSA Fellowships	Trainee.		67,564	1.3%
R&D Contracts	R&D Contracts	399	588,742	11.6%
	SBIR Contracts	71	25,020	0.5%
	Subtotal, Contracts	470	613,762	12.0%
Intramural Research	Program		676,730	13.3%
	NIH Management Fund/SSF Assessment	1.004	128,602	2.5%
	Subtotal, Intramural Research FTE	s: 1,934	805,332	15.8%
RMS	Research Mgmt and Support		345,412	6.8%
	NIH Management Fund/SSF Assessment		36,353	0.7%
	Subtotal, RMS FTE	s: 1,122	381,765	7.5%
Buildings and Facilitie	es .		7,920	0.2%
Construction			0	0.0%
*Total NCI	FTE	s: 3,056	5,098,147	100.0%

^{*}EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

ivision Oollars in Ti	_	tions by	Mecha	nism,	Fiscal `	Year 20	010		
	•							Research	Program
CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Grants	Support
								1,461,515	75,32
								28,947	
								516,598	
								2,007,060	75,329
								85,669	
								2,092,729	75,329
							295,856		•
		133,193					617		
		16,095		22,039	400		231		
		7,595	29,848	920			104,339		
		156,883	29,848	22,959	400		401,043		
		100,000	20,040	22,505	700		401,040		
							10,823		
							3,134		
							13,278		
							12,408		
							12,922		
							4,963		
							5,812		
							3,422		
							3,311		
							3,311		
							4,841		
							74,914		
							35,444		
		154,279			93,624		6,584		
								466	
								1,348	
								685	
								67,144	
								862	
								5,599	
								1,664	
		154,279	0	0	93,624		42,028	77,768	
		311,162	29,848	22,959	94,024		517,985	2,170,497	75,329
		011,100		,_,	,		67,564		,
	28,675	120,341	515	72,775	51,470		220,544		94,422
	- ,	2,2	2.9	,	- ,		25,020		, -
	28,675	120,341	515	72,775	51,470		245,564		94,42
438,887	67,401			,	,		159,461		10,98
									128,60
438,887	67,401						159,461		139,58
		46,533	10,106	32,079	16,943	22,584	176,126		41,04
									36,35
		46,533	10,106	32,079	16,943	22,584	176,126		77,39
		<i>'</i>		,	,		7,920		•
438,887	96,076	478,036	40,469	127,813	162,437	22,584	1,174,620	2,170,497	386,728

NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2010

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$100,777	61.1%
Center for Scientific Review	9,564	5.8%
Center for Information Technology	4,919	3.0%
Service and Supply Fund Assessment	16,325	9.9%
Other Research Services	13,661	8.3%
Other OD	19,709	12.0%
*Total Management Fund and SSF	164,955	100.0%
Other NIH Institutes Management Fund and SSF	1,418,920	
Total NIH Management Fund and SSF	\$1,583,875	

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition service, housekeeping services, laundry, and social work.

Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.

GSA Rental Payments for Space: All building rental costs, including utilities and guard services.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, and biomedical engineering.

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

NCI CRADA Receipts Deposited to the U.S. Treasury

	(Dollars in Thousands)								
	Carryover								
	from Prior								
Fiscal Year	Year	Collections	Obligations						
1999	9,302	3,645	4,707						
2000	8,240	2,717	4,618						
2001	6,339	5,295	2,770						
2002	8,864	5,048	2,380						
2003	11,533	5,221	5,361						
2004	11,351	5,080	5,469						
2005	10,962	6,858	4,253						
2006	13,567	6,142	7,125						
2007	12,584	9,410	8,360						
2008	13,634	6,677	7,200						
2009	13,111	5,466	4,765						
2010	13,813	5,024	5,644						

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange, and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH.

NCI Royalty Income Funding History (Dollars in Thousands)

	(Dollars III Tribusarius)								
		Inventor							
Years	Collections*	Payments	Other						
1999/2000	21,160	4,695	16,465						
2000/2001	37,040	4,811	32,229						
2001/2003	27,443	6,210	21,233						
2002/2004	42,565	3,961	38,604						
2003/2005	27,271	5,262	22,009						
2004/2006	26,923	4,950	21,973						
2005/2007	34,086	5,745	28,341						
2006/2008	29,811	6,853	22,958						
2007/2009	36,344	7,210	29,134						
2008/2010	50,269	8,192	42,077						
**2009/2011	51,621	10,223	41,398						
**2010/2012	58,515	12,305	46,210						

^{*}Does not include assessments by NIH.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997, extended in July 2000 (PL 106-253) and November 2005 (PL 109-100) and again in December 2007 (PL 110-150). This act allows postal customers to contribute funding to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service. Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of October 2010, NCI has received \$48,841,212. NCI has used these funds for research projects directed towards breast cancer research. Thus far, four major programs have been funded -- the "Insight Awards to Stamp Out Breast Cancer," the "Breast Cancer Research Stamp Exception Program," the "Breast Cancer Premalignancy Program" and a clinical trial to determine the risk of breast cancer recurrence. In FY 2010, \$2.590 million was obligated on Breast Cancer Stamp Fund programs.

^{**2009/2011} and 2010/2012 collections and payments are estimates.


The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

Disease Area	2006 Actual	2007 Actual	2008 Actual	2009 Actual	2010 Actual
Total NCI Budget	\$4,747.2	\$4,792.6	\$4,827.6	\$4,966.9	\$5,098.1
AIDS	253.7	253.7	258.5	265.9	272.1
Brain & CNS	130.3	148.2	153.7	151.5	156.8
Breast Cancer	584.7	572.4	572.6	599.5	631.2
Cervical Cancer	83.3	82.4	76.8	77.8	77.0
Clinical Trials	822.3	843.7	853.2	846.6	852.3
Colorectal Cancer	244.1	258.4	273.7	264.2	270.4
Head and Neck Cancers	71.3	66.2	76.1	77.1	62.7
Hodgkins Disease	20.9	16.5	17.5	18.2	14.6
Leukemia	223.5	205.5	216.4	220.6	239.7
Liver Cancer	62.7	67.7	74.2	70.3	72.6
Lung Cancer	242.9	226.9	247.6	246.9	281.9
Melanoma	108.0	97.7	110.8	103.7	102.3
Multiple Myeloma	30.3	32.3	41.5	45.2	48.5
Non Hodgkin's Lymphoma	114.1	113.0	122.6	130.9	122.4
Ovarian Cancer	95.1	96.9	100.0	110.1	112.3
Pancreatic Cancer	74.2	73.3	87.3	89.7	97.1
Prostate Cancer	293.2	296.1	285.4	293.9	300.5
Stomach Cancer	11.5	12.0	12.4	15.4	14.5
Uterine Cancer	19.4	16.6	17.1	18.0	14.2

Note: These figures were created using NCI's coding methodology. More information about this methodology, as well as project listings for these categories and others, are available online through NCI's Funded Research Portfolio website. http://fundedresearch.cancer.gov/

Research Project Grants Number of Awards Fiscal Years 2001-2010

Includes Small Business Innovation Research and Small Business Technology Transfer Awards



 $^{^\}star \textsc{EXCLUDES}$ projects awarded with Stamp Out Breast Cancer Funds.

RPGs Requested and Awarded Fiscal Years 2001-2010

(Dollars in Thousands)

Fiscal Year		Туре	Requested		Award		Success
	Competing	New .	4342	\$1,374,538	1050	\$290,707	
		Renewal	856	437,455	372	173,722	
2001		Supplement	29	11,108	6	1,214	
		Subtotal	5227	1,823,101	1428	465,643	27.3%
	Non-Competing				3267	1,213,098	
	Total				4695	1,678,741	
	Competing	New	4539	\$1,407,475	1142	\$302,217	
		Renewal	861	404,789	384	186,087	
2002		Supplement	42	8,512	21	3,499	
		Subtotal	5442	1,820,776	1547	491,803	28.4%
	Non-Competing				3429	1,356,138	
	Total				4976	1,847,941	
	Competing	New	5323	\$1,675,039	1222	\$347,446	
	, ,	Renewal	955	447,122	441	194,084	
2003		Supplement	20	4,671	5	1,338	
		Subtotal	6298	2,126,832	1668	542,868	26.5%
	Non-Competing			, -,	3467	1,457,144	
	Total				5135	2,000,012	
	Competing	New	6,558	\$2,045,451	1,333	\$339,925	
		Renewal	988	518,201	445	210,790	
2004		Supplement	24	8,337	7	2,196	
		Subtotal	7,570	2,571,989	1,785	552,911	23.6%
	Non-Competing	oubtotu.	.,0.0	2,011,000	3,682	1,549,727	20.070
	Total				5,467	2,102,638	
	Competing	New	6,357	\$2,239,503	1,086	\$309,507	
	Competing	Renewal	1,050	473,898	335	162,857	
2005		Supplement	22	6,147	7	1,185	
2005		Subtotal	7,429	2,719,548	1,428	473,549	19.2%
	Non-Competing	Subiolai	1,423	2,719,540	3,984	1,656,614	13.2/0
	Total				5,412	2,130,164	
	Competing	New	6,585	\$2,215,548	1,105	\$293.912	
	Competing	Renewal	984		,	*,-	
0000				542,799	348	170,110	
2006		Supplement	13	4,098	2	681	10.00/
		Subtotal	7,582	2,762,445	1,455	464,703	19.2%
	Non-Competing				3,980	1,633,442	
	Total		0.400	#0.110.000	5,435	2,098,145	
	Competing	New	6,428	\$2,116,286	1,178	\$306,431	
		Renewal	864	482,655	295	163,225	
2007		Supplement	12	3,513	2	609	
	l	Subtotal	7,304	2,602,454	1,475	470,265	20.2%
	Non-Competing				3,997	1,582,828	
	Total				5,472	2,053,093	
	Competing	New .	5,944	\$1,991,089	1,150	\$324,070	
		Renewal	966	515,784	352	187,458	
2008		Supplement	1	408	1	338	
		Subtotal	6,911	2,507,281	1,503	511,866	21.7%
	Non-Competing				3,877	1,509,611	
	Total				5,380	2,021,477	
	Competing	New	6,167	\$2,069,518	1,029	\$320,980	
	- 5psig	Renewal	1,000	500,201	358	177,853	
2009		Supplement	5	1,141	1	67	
		Subtotal	7,172	2,570,860	1,388	498,900	19.4%
	Non-Competing	Gubiolai	1,112	2,570,000	3,791	1,564,139	13.7/0
	Total			-	5,179	2,063,039	
	Competing	New	7,494	\$2,776,315	1,041	\$375,830	
		Renewal	1,007	591,060	343	183,675	
2010		Supplement	18	6,805	3	1,491	
		Subtotal	8,519	3,374,180	1,387	560,996	16.3%
	Non-Competing				3,692	1,531,733	
	Total				5,079	2,092,729	


Includes Small Business Innovation Research and Small Business Technology Transfer Awards.
Success rate is the number of awarded grants divided by the number of awards requested.
Totals exclude Assessments for Program Evaluation and projects awarded with Stamp Out Breast Cancer Funds.

RPG Awards by Activity Codes

Fiscal Years 2001-2010

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	DP1	DP2	P01	R00	R35	R37	R29	RFA	U01	U19	R03	R21	R33	R15	R55	R56	SBIR/ STTR	TOTAL
2001	#	3,231			178		1	61	210	260	18		122	231	49	3	3		328	4,695
2001	\$	1,008,199			301,115		2,186	26,682	23,738	150,224	14,873		9,024	42,326	23,883	358	300		75,833	1,678,741
2002	#	3,376			173			65	112	267	17		186	308	79	10	9		374	4,976
2002	\$	1,093,908			317,632			29,445	12,471	177,195	17,531		14,115	57,633	39,317	1,477	850		86,367	1,847,941
2003	#	3,573			178			70	14	252	27		203	360	81	21			356	5,135
2003	\$	1,207,387			336,607			35,360	1,584	173,342	31,126		15,207	67,742	37,714	3,086			90,857	2,000,012
2004	#	3,780			177			73	0	233	26		240	425	96	20			397	5,467
2004	\$	1,277,185			344,489			37,888	53	168,539	31,377		18,067	77,970	42,931	4,560			99,579	2,102,638
2005	#	3,848			176			74		254	30	1	223	430	88	20	2	1	265	5,412
	\$	1,312,762			338,660			40,007		171,403	34,100	1,049	16,894	76,566	36,250	4,091	200	407	97,775	2,130,164
2006	#	3,909			173			76		273	26	3	218	405	73	14		2	263	5,435
	\$	1,293,880			339,616			40,067		173,304	31,292	4,365	16,558	70,650	28,726	2,983		649	96,055	2,098,145
2007	#	3,849			172			73		285	22	3	284	437	48	19		2	278	5,472
	\$	1,266,622			326,968			38,232		177,423	24,295	4,212	21,640	78,748	16,739	4,042		495	93,677	2,053,093
2008	#	3,732	2		158	2		70		294	25	3	256	466	36	22		2	312	5,380
	\$	1,250,346	1,651		305,250	497		36,287		174,254	20,872	4,366	19,597	92,120	13,770	4,725		302	97,439	2,021,476
2009	#	3,573	3		151	29		63		326	32	2	239	447	25	27	1		261	5,179
	\$	1,248,939	3,313		302,270	7,186		32,640		218,798	31,320	1,584	18,401	91,537	9,094	5,823	100	79	91,954	2,063,038
2010	#	3,655	5	1	140	55		61		275	43	1	181	415	16	24			207	5,079
	\$	1,323,673	6,021	2,512	280,531	13,665		31,498		200,424	36,209	1,252	14,195	83,950	5,583	7,539		8	85,669	2,092,729



 $^{^{\}star}\textsc{EXCLUDES}$ projects awarded with the Stamp Out Breast Cancer Funds and Program Evaluation.

Activity	Code	Descriptions
----------	------	--------------

R01	Research Project (Traditional) - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
DP1	NIH Director's Pioneer Award (NDPA) - Support for individuals who have the potential to make extraordinary contributions to medical research. Not renewable
DP2	NIH Director's New Innovator Awards support exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact. This award complements ongoing efforts by NIH and its institutes and centers to fund new investigators through R01 grants and other mechanisms.
P01	Research Program Projects - broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R00	Research Transition Award - To support the second phase of a Career/Research Transit award program that provides 1-3 years of independent research support (R00) contingenton securing an independent research position. Award recipients will be expected to contract successfully for independent R01 support from the NIH during the R00 research transition award period.
R35	Outstanding Investigator Grants - long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	Methods to Extend Research in Time (MERIT) Award - long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	First Independent Research Support and Transition (FIRST) Award - sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	Request for Applications - A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
U01	Research Project Cooperative Agreement - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
U19	Research Program Cooperative Agreements - support research programs that have multiple projects directed towards specific major objective, basic theme, or program goal, requiring a broad-based, multidisciplinary, and often long term, approach.
R03	Small Grants - research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R15	Academic Research Enhancement Award (AREA) - to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R21	Exploratory/Developmental Grants - Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	Exploratory/Developmental Grants - Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R55	Shannon Awards - limited support to scientists whose research applications fall short of the cutoff for funding yet are a the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R56	High-Priority, Short-Term Project Award - provide limited, non-renewable interim support to enable an applicant to gather additional data for revision of a new or competing renewal application.
R41	Small Business Technology Transfer (STTR) Grants - Phase I - limited support to projects conducted jointly by a small business concern and a research institution in which not less than 40% of the work is performed by the small business.
R42	Small Business Technology Transfer (STTR) Grants - Phase II - limited support to projects conducted jointly by a small business concern and a research institution in which not less than 40% of the work is performed by the small business.
R43	Small Business Innovation Research (SBIR) Grants - Phase I - projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to commercial products or services.
R44	Small Business Innovation Research (SBIR) Grants - Phase II - in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.
U43	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase I - utilized when an assistance relationship will exist between the institute and a recipient and in which substantial programmatic involvement is anticipated between the institute and the recipient during performance of the contemplated activity. Supports projects limited in time and amount to establish the technical merit and feasibility of R&D ideas which may ultimately lead to commercial products or services.
U44	Small Business Innovation Research (SBIR) Cooperative Agreement - Phase II - utilized when an assistance relationship will exist between the institute and a recipient and in which substantial programmatic involvement is anticipated between the institute and the recipient during performance of the contemplated activity. Supports in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

Cancer Centers by State (P30 Core Grants), Fiscal Year 2010

(Dollars in Thousands)

Arzona	(Dollars in Thousands) State	Grantee Institution	Code	Count	Amount
California Burnham Institute for Medical Research (City of Hope/Beckman Research Institute Comprehensive Salk Institute for Biological Studies Basic 1 3,096 Stanford University of California Davis University of California Los Angeles Comprehensive 1 1,055 University of California San Francisco Comprehensive 1 4,757 University of California San Diego Comprehensive 1 4,757 University of California San Francisco Comprehensive 1 1,076 University of Colorado Deriver Comprehensive 1 1,077 University of Colorado Deriver Comprehensive 1 1,077 University Office California University Comprehensive 1 1,077 University Office California University Office California University Office Offi		•	Comprehensive		\$6,189
City of Hope/Beckman Research Institute Sakin Institute for Biological Studies Basic 1 3,096			Comprehensive	1	4,362
Salik Institute for Biological Studies Stanford University of California Davis University of California Davis University of California Los Angeles University of California Los Angeles University of California Los Angeles Comprehensive University of California Los Angeles University of California San Francisco Comprehensive University of California San Francisco Comprehensive University of California San Francisco Comprehensive University of Colorado Denver Comprehensive University of California San Francisco Comprehensive University of California Comprehensive University of California Comprehensive University of California Comprehensive University of Canada University of Lawaii at Manoa University of Chicago Comprehensive University of Maryland Baltimore	California	Burnham Institute for Medical Research	Basic	1	4,210
Stanford University California Davis University of California Invine University of California Invine Comprehensive 1 1,460 University of California Los Angeles Comprehensive 1 5,515 University of California San Diego Comprehensive 1 7,776 University of California San Diego Comprehensive 1 7,776 University of California San Diego Comprehensive 1 7,776 University of California San Prancisco Comprehensive 1 7,776 University of Colorado Denver Comprehensive 1 1,455 Connecticut Vale University Comprehensive 1 1,278 Comprehensiv			•		2,520
University of California Davis University of California Los Angeles University of California Los Angeles University of California Los Angeles University of California San Francisco University of California San Francisco Comprehensive 1 7,767 Calorado University of Colorado Deriver Comprehensive 1 6,767 Calorado University of Colorado Deriver Comprehensive 1 1,767 Calorado University of Colorado Deriver Comprehensive 1 2,456 Connecticut 7 491e University 1 2,000 Comprehensive 1 2,200 Dist of Col Georgetown University 1 2,000 Dist of Col Georgetown University 1 3,166 Georgia Emory University 1 3,166 Georgia Indiana University of University 1 3,166 Georgia Indiana University of University 1 3,166 Indiana Indiana University of University 2 3,166 Indiana Indiana University of University 3 4,566 Indiana Indiana University of University 3 5,147 Indiana 4 1,455 Indiana 4					3,090
University of California Los Angeles 1,460 1,461					·
University of California Los Angeles University of California San Diego University of California San Diego University of California San Francisco Comprehensive University of Southern California Comprehensive 1, 7,676 Colorado University of Southern California Comprehensive 1, 4,456 Connecticut Vale University Comprehensive 1, 2,088 Connecticut Vale University Comprehensive 1, 2,088 Dist of Col Georgetown University Comprehensive 1, 1,272 Florida H. Lee Moffitt Geneer Center & Research Institute Comprehensive 1, 1,272 Florida L. Lee Moffitt Geneer Center & Research Institute Comprehensive 1, 1,346 Georgia Emory University University of Hawaii at Manoa Unical University of Chicago Comprehensive 1, 1,456 Indiana University of Chicago Comprehensive University of Chicago University of Chicago Comprehensive University of Chicago University of Manoa Massachusetts Dana-Farber Cancer Institute Comprehensive University of Manoa University of Manoa University of Manoa Massachusetts Institute of Technology Massachusetts Massachusetts Institute of Technology Massachusetts Massachusetts Institute of Technology Comprehensive Massachusetts Institute of Technology Massachusetts Massachusetts Institute of Technology Comprehensive Massachusetts Institute of Technology Comprehensive Massachusetts Institute					
University of California San Diego University of California San Transioso University of California San Fransioso University of California San Fransioso University of Colardon Denver Comprehensive 1 6,737 Colorado University of Colorado Denver Comprehensive 1 2,086 Connecicut Yale University Comprehensive 1 2,086 Comprehensive 1 3,162 Corriorado H. Lee Moffitt Cancer Center & Research Institute Comprehensive 1 3,162 Corriorad H. Lee Moffitt Cancer Center & Research Institute Comprehensive 1 1,727 Colorado H. Lee Moffitt Cancer Center & Research Institute Comprehensive 1 1,164 Corriorad H. Lee Moffitt Cancer Center & Research Institute Comprehensive 1 1,164 Corrioration Hawaii University of Chicago Comprehensive 1 1,164 Corrioration University of Chicago Comprehensive 1 1,164 Corrioration Corrio		1	•		
University of California San Francisco University of Southern California Comprehensive 1 (A.53 Colorado University of Southern California Comprehensive 1 (A.45 Comnecticut Yale University Comprehensive 1 (A.53 Connecticut Yale University Comprehensive 1 (A.53 Comprehensive 1 (A.54 Comprehensive 1 (A.55 Comp		,	•		
University of Southern California Comprehensive 1 (5.73) Connecticut Vale University Comprehensive 1 (2.08) Bills of Coll Georgstown University Comprehensive 1 (2.08) Bills of Coll Georgstown University Comprehensive 1 (3.16) Florida H. Lee Moffitt Cancer Center & Research Institute Comprehensive 1 (3.16) Georgia Emory University Cinical 1 (3.16) Georgia Emory University Cinical 1 (3.16) Hawaii University of Hawaii at Manoa Cinical 1 (3.16) Hawaii University of Chicago Comprehensive 1 (3.16) Indiana Indiana Univ-Purdue Univ at Indianapolis Comprehensive 1 (3.16) Indiana Indiana Univ-Purdue Univ at Indianapolis Cinical 1 (3.15) Indiana Indiana Univ-Purdue Univ at Indianapolis Cinical 1 (3.15) Walliano University of Statayette 8 (3.15) Indiana Indiana Univ-Purdue Univ at Indianapolis Cinical 1 (3.15) Indiana Indiana Univ-Purdue Univ at Indianapolis Cinical 1 (3.15) Walliano University of Indiana University of Maryland Baltimore Cinical 1 (3.15) Wassachusetts Indiana University of Maryland Baltimore Cinical 1 (3.15) Wassachusetts Institute of Technology Basic 1 (3.25) Winnesota Mayo Clinic Rochester Cancer Institute Comprehensive 1 (3.05) Wayne State University of Michigan at Ann Arbor Comprehensive 1 (3.05) Wayne State University (4.05) Wayne State University (4.05) Wayne State University (4.05) Wayne State University (4.05) Wayne State University (5.05) Wayne State (5.05) Wayne Stat					·
Colorado University of Colorado Denver Comnecticut Vale University Comprehensive 1 (2,088 Dist of Col Georgetown University Florida H. Lee Moffill Cancer Center & Research Institute Comprehensive 1 (3,162 Georgia Emory University Comprehensive 1 (1,152 Florida Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,154 Lee Moffill Cancer Center & Research Institute Comprehensive 1 (1,158 Lee Moffill Cancer Center Institute Comprehensive 1 (1,158 Lee Moffill Cancer Comprehensive 1 (1,158 Lee Moffi		1			
Connecticut Vale University Comprehensive 1 2.086	Colorado		· · · · · · · · · · · · · · · · · · ·		
Dist of Col Georgetown University 1,127 Florida L. Lee Moffitt Cancer Conter & Research Institute Comprehensive 1 1,36 Georgia Emory University Cilinical 1 1,54 Hawaii University of Hawaii at Manoa Cilinical 1 1,54 Hawaii University of Hawaii at Manoa Cilinical 1 1,54 Hawaii University of Chicago Comprehensive 1 4,56 Illinois Northwestern University Comprehensive 1 4,56 Illinois Indiana University of Chicago Comprehensive 1 4,56 Indiana Indiana University of Iowa Comprehensive 1 4,56 Indiana University of Iowa Comprehensive 1 4,56 Illinois Dinary of Iowa Din			<u> </u>		
Florida					1,727
Caeorgia					3,162
Hawaii University of Hawaii at Manoa Clinical 1 1,544 lininis Northwestern University Comprehensive 1 4,565 lindiana Indiana University of Chicago Comprehensive 1 4,565 lindiana Indiana University West Lafayette Basic 1 1,255 lowa University of Iowa Comprehensive 1 1,255 lowa University of Maryland Baltimore Clinical 1 1,555 lowa Sachusetts Dana-Farber Cancer Institute Of Technology Basic 1 4,057 linkingan University of Maryland Baltimore Clinical 1 1,855 linkingan University of Minespota Ann Arbor Comprehensive 1 6,099 linkingan University of Minespota Twin Cities Comprehensive 1 6,099 linkingan University of Minespota Twin Cities Comprehensive 1 1,855 linkingan University Of Minespota Twin Cities Comprehensive 1 1,855 linkingan University Of Minespota Twin Cities Comprehensive 1 1,814 linkingan University Of Minespota Twin Cities Comprehensive 1 1,814 linkingan University Of Minespota Twin Cities Comprehensive 1 1,814 linkingan University Of Methraka Medical Center Clinical 1 1,544 linkingan University Of Nebraka Medical School Comprehensive 1 3,576 linkingan University Of New Mexico University Citical 1 2,276 linkingan University Health Sciences Comprehensive 1 3,576 linkingan University Health Sciences Comprehensive 1 4,268 linkingan University Health Sciences Comprehensive 1 4,268 linkingan University Health Sciences Comprehensive 1 4,368 linkingan University Health Sciences Comprehensive 1 4,368 linkingan University Of North Carolina Chapel hill Comprehensive 1 4,368 linkingan University Of North Carolina Chapel hill Comprehensive 1 4,368 linkingan University Of North Carolina Chapel hill Comprehensive 1 4,368 linkingan University Of North Carolina Chapel hill Comprehensive 1 4,368 linkingan University	Georgia		<u> </u>	1	1,694
University of Chicago		University of Hawaii at Manoa	Clinical	1	1,540
Indiana	Illinois	Northwestern University	Comprehensive	1	5,147
Purdue University Vest Lafayette Basic			Comprehensive		4,569
Inwampathe	Indiana		Clinical		1,452
Maine Jackson Laboratory Basic 1 2.256 Maryland Johns Hopkins University Comprehensive 1 7,855 Massachusetts Dana-Farber Cancer Institute Comprehensive 1 1,555 Massachusetts Massachusetts Institute of Technology Basic 1 1,659 Michigan University of Michigan at Ann Arbor Comprehensive 1 6,099 Wayne State University Comprehensive 1 6,099 Minnesota Mayo Clinic Rochester Comprehensive 1 6,017 Missouri Washington University Comprehensive 1 4,761 New Hampshire Dartmouth College Comprehensive 1 3,575 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,575 New Mexico University of New Mexico Colimbia University Health Sciences Comprehensive 1 4,027 New York Albert Einstein College of Medicine Comprehensive 1 4,136 Columbia University Health Sciences					1,258
Maryland Johns Hopkins University Comprehensive 1 1,555 University of Maryland Baltimore Clinical 1,555 Massachusetts Dana-Farber Cancer Institute Comprehensive 1 1,188 Massachusetts Institute of Technology Basic 1 4,055 Michigan University of Michigan at Ann Arbor Comprehensive 1 6,095 Wayne State University of Michigan at Ann Arbor Comprehensive 1 6,095 Wayne State University of Minnesota Twin Cities Comprehensive 1 6,095 Washington University of Minnesota Twin Cities Comprehensive 1 3,811 Washington University Comprehensive 1 4,765 New Hampshire Dartmouth College Comprehensive 1 1,545 New Hampshire Dartmouth College Comprehensive 1 3,576 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,576 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,576 New Mexico University of New Mexico Collinical 1 4,207 Cold Spring Harbor Laboratory Columbia University Health Sciences Comprehensive 1 4,267 New York University School of Medicine Comprehensive 1 4,365 Noar-Kettering Institute Corp Comprehensive 1 4,365 Noar-Kettering Institute for Cancer Res Comprehensive 1 4,365 Noar-Kettering Institute for Cancer Res Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 North Carolina Wake Forest University Health Sciences Comprehensive 1 6,307 Oregon Oregon Health and Science University Comprehensive 1 6,307 Oregon Oregon Health and Science University Comprehensive 1 6,307 North Carolina State University Of North Carolina Chapel hill Comprehensive 1 6,307 North Carolina New York University Of Porthy Ward Science University Comprehensive 1 6,307 North Carolina New York University Of Porthy Ward Science University Comprehensive 1 6,307 North Carolina New York University Of Porthy Ward Science University Comprehensive 1 6,307 North Carolina New York Caro			· · · · · · · · · · · · · · · · · · ·		1,885
University of Maryland Baltimore Dana-Farber Cancer Institute Dana-Farber Cancer Comprehensive Dana-Farber Cancer Cancer Comprehensive Dana-Farber Cancer Cancer Cancer Cancer Comprehensive Dana-Farber Cancer Cancer Comprehensive Dana-Farber Cancer Cance					
Massachusetts Dana-Farber Cancer Institute Comprehensive Hassis 1 1.888 Massachusetts Institute of Technology Basic 1 4.957 Michigan University of Michigan at Ann Arbor Comprehensive 1 6.095 Minnesota Mayo Clinic Rochester Comprehensive 1 6.017 Minnesota University of Minnesota Twin Cities Comprehensive 1 3.811 Missouri Washington University Comprehensive 1 4.761 New Harsak University of Nebraska Medical Center Clinical 1 1,542 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,578 New York Albert Einstein College of Medicine Yeshiva University Clinical 1 4,202 New York Vork University School of Medicine Comprehensive 1 4,202 Cold Spring Harbor Laboratory Comprehensive 1 4,202 Cold Spring Harbor Laboratory Comprehensive 1 4,202 Cold Spring Harbor Laboratory Comprehensive 1	Maryland		•		
Massachusetts Institute of Technology Michigan University of Michigan at Ann Arbor Comprehensive 1 2,594 Minnesota Mayo Clinic Rochester University of Minnesota Twin Cities Comprehensive 1 4,761 Nebraska Missouri Washington University Comprehensive 1 4,761 New Hampshire Dartmouth College Comprehensive 1 3,578 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,164 New Mexico University of New Mexico Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Cold will university Health Sciences Comprehensive 1 4,237 New York Chriversity School of Medicine Roswell Park Cancer Institute Corp Sloan-Kettering Institute for Cancer Res Comprehensive 1 4,378 North Carolina Duke University of New School Duke University of New School Duke University Only Comprehensive 1 4,368 Wake Forest University Health Sciences Comprehensive 1 1,608 Ohio Case Western Reserve University Comprehensive 1 1,608 Ohio Case Wes	Managalayaatta				
Michigan University of Michigan at Ann Arbor Comprehensive Yayne State University Comprehensive 1 2,594 Minnesota Mayo Clinic Rochester Comprehensive 1 3,811 Missouri Washington University Comprehensive 1 3,811 Missouri Washington University Comprehensive 1 4,761 Nebraska University of Minnesota Twin Cities Comprehensive 1 1,542 New Hampshire Dartmouth College Comprehensive 1 3,572 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,167 New Mexico University of New Mexico Comprehensive 1 3,167 New Work Albert Einstein College of Medicine Yeshiva University Collinical 1 2,276 New York Albert Einstein College of Medicine Yeshiva University Collumbia University Health Sciences Comprehensive 1 4,167 New York University School of Medicine Clinical 1 2,264 Roswell Park Cancer Institute Corp Comprehensive 1 4,368 Sloan-Kettering Institute for Cancer Res Comprehensive 1 4,368 Sloan-Kettering Institute for Cancer Res Comprehensive 1 4,368 Sloan-Kettering Institute for Cancer Res Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 Ohio Case Western Reserve University Comprehensive 1 5,427 Ohio State University Comprehensive 1 5,427 Ohio State University Comprehensive 1 5,427 Oregon Oregon Health and Science University Comprehensive 1 5,427 Ohio State University Comprehensive 1 5,427 University of Pittsburgh Comprehensive 1 6,307 University of Texas San Antonio Health Science Center University 1 6,304 University of Texas San	Massachusells		•		
Mayne State University	Michigan	0,			
Minnesota Mayo Clinic Rochester University of Minnesota Twin Cities Comprehensive 1 3,811 Missouri Washington University Comprehensive 1 3,811 Nebraska University of Nebraska Medical Center Clinical 1 1,543 New Hampshire Dartmouth College Comprehensive 1 3,576 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,576 New Mexico University of New Mexico Clinical 1 2,276 New York Albert Einstein College of Medicine Yeshiva University Cold Spring Harbor Laboratory Columbia University Health Sciences Comprehensive 1 4,023 Columbia University Health Sciences Comprehensive 1 4,117 New York University School of Medicine Properties of Comprehensive 1 4,365 Sloan-Kettering Institute for Cancer Res Comprehensive 1 4,365 Sloan-Kettering Institute For Cancer Res Comprehensive 1 6,303 North Carolina Wake Forest University Health Sciences Comprehensive 1 6,305 Ohio Case Western Reserve University Comprehensive 1 1,606 Oregon Oregon Health and Science University Comprehensive 1 1,327 Oregon Health a	Michigan	, ,	•		
University of Minnesota Twin Cities	Minnesota				
Missouri Washington University Comprehensive 1 4.761 New Hampshire Darmouth College Comprehensive 1 3,578 New Jersey Robert Wood Johnson Medical School Comprehensive 1 3,160 New Mexico University of New Mexico Clinical 1 2,276 New York Albert Einstein College of Medicine Yeshiva University Cold Spring Harbor Laboratory Columbia University Health Sciences Comprehensive 1 4,131 New York University Health Sciences Comprehensive 1 4,236 Columbia University School of Medicine Clinical 1 2,644 Roswell Park Cancer Institute Corp Comprehensive 1 4,365 Sloan-Kettering Institute For Cancer Res Comprehensive 1 4,365 Sloan-Kettering Institute For Cancer Res Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,899 Wake Forest University Comprehensive 1 6,899 Oregon Case Western Reserve University Comprehensive 1 5,427 Ohio State University Comprehensive 1 6,897 Oregon Oregon Health and Science University Clinical 1 1,295 Pennsylvania Fox Chase Cancer Center 1 Comprehensive 1 8,491 Thomas Jefferson University Clinical 1 1,295 University of Pennsylvania Comprehensive 1 5,510 University of Pennsylvania Comprehensive 1 5,510 University of Pennsylvania Comprehensive 1 6,225 South Carolina Medical University Comprehensive 1 6,225 Vanderbilt University Texas Southwestern Medical Center Clinical 1 1,875 Texas Baylor College of Medicine Clinical 1 1,587 University of Texas Southwestern Medical Center Clinical 1 1,568 University of Texas Southwestern Medical Center Clinical 1 1,568 University of Texas Southwestern Medical Center Clinical 1 1,568 Uriginia Commonwealth University Clinical 1 1,466 University of Texas Southwestern Medical Center Clinical 1 1,466 University of Texas Southwestern Medical Center Clinical 1 1,466 University of Texas Southwestern Medical Center Clinical 1 1,466 University of Texas Southwestern Medical Center Clinical 1 1,466 University of Texas Southwestern Medical Center Clinical 1 1,466 University of Virginia Charlott	Will in looo to				*
Nebraska	Missouri		· · · · · · · · · · · · · · · · · · ·		4,761
New Hampshire Robert Wood Johnson Medical School Comprehensive 1 3,160 New Mexico University of New Mexico College of Medicine Yeshiva University Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Basic Columbia University Health Sciences Comprehensive 1 4,236 Columbia University Health Sciences Comprehensive 1 4,317 New York University Health Sciences Comprehensive 1 4,346 Roswell Park Cancer Institute Corp Comprehensive 1 4,346 Soloan-Kettering Institute for Cancer Res Comprehensive 1 4,347 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University of North Carolina Chapel hill Comprehensive 1 6,307 University Ohio State University University Comprehensive 1 6,307 Comprehensive 1 6,307 University Origon Pleatht and Science University Comprehensive 1 1,295 Pennsylvania Fox Chase Cancer Center Comprehensive 1 1,295 University of Pennsylvania Comprehensive 1 1,295 University of Pennsylvania Comprehensive 1 1,295 University of Pennsylvania Comprehensive 1 1,205 University of Pittsburgh Comprehensive 1 5,510 Wistar Institute Basic 1 2,627 South Carolina Medical University of South Carolina Clinical 1 1,875 University of Texas M.D. Anderson Cancer Center University Comprehensive 1 1,445 University of Texas Southwestern Medical Center University of Texas Southwestern Medical Center University of University of University Clinical 1 1,465 University of University of University Clinical 1 1,465 University of University of University Clinical 1 1,565 University of University			<u> </u>	1	1,543
New Mexico New York Albert Einstein College of Medicine Yeshiva University Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory Columbia University Health Sciences Comprehensive New York University School of Medicine Roswell Park Cancer Institute Corp Sloan-Kettering Institute For Cancer Res Comprehensive University Comprehensive University Or North Carolina Chapel hill University of North Carolina Chapel hill Comprehensive University Oregon Health and Science University Comprehensive Oregon Oregon Oregon Health and Science University Comprehensive Thomas Jefferson University Comprehensive University of Pittsburgh at Pittsburgh Fox Chase Cancer Center University of Pittsburgh at Pittsburgh Wistar Institute South Carolina Tennessee St. Jude Children's Research Hospital University of Texas San Antonio Health Science Center University of Texas San Antonio Health Science Center University of Texas San Antonio Health Science Center University of Virginia Charlottesville University of Virginia Charlottesville University of Virginia Charlottesville University of Virginia Cancer Medical Center University of Texas San Antonio Health Science Center University of Texas San Antonio Health Science Center University of Virginia Comprehensive University of Virginia Charlottesville University of Virginia Componeweal University of Virginia Comp	New Hampshire	· · · · · · · · · · · · · · · · · · ·	Comprehensive	1	3,578
New York	New Jersey	Robert Wood Johnson Medical School	Comprehensive	1	3,160
Cold Spring Harbor Laboratory Columbia University Health Sciences Comprehensive New York University School of Medicine Roswell Park Cancer Institute Corp Sloan-Kettering Institute For Cancer Res Comprehensive Sloan-Kettering Institute for Cancer Res Comprehensive University of North Carolina Chapel hill Wake Forest University Comprehensive University of North Carolina Chapel hill Comprehensive Comprehensive University of North Carolina Chapel hill Comprehensive Comprehensive Comprehensive University of University Comprehensive Clinical Cl	New Mexico	University of New Mexico	Clinical	1	2,276
Columbia Üniversity Health Sciences New York University School of Medicine Roswell Park Cancer Institute Corp Sloan-Kettering Institute for Cancer Res Comprehensive Sloan-Kettering Institute for Cancer Res Comprehensive University of North Carolina Chapel hill Comprehensive University of North Carolina Chapel hill Comprehensive University of North Carolina Chapel hill Comprehensive Comprehen	New York			1	4,027
New York University School of Medicine Roswell Park Cancer Institute Corp Comprehensive 1 4,366					4,236
Roswell Park Cancer Institute Corp Comprehensive 1 4,368					4,117
Sloan-Kettering Institute for Cancer Res Comprehensive 1 14,375		,			
North Carolina Duke University Duniversity of North Carolina Chapel hill Comprehensive 1 6,307 6,898 Wake Forest University Health Sciences Comprehensive 1 1,608 Case Western Reserve University Comprehensive 1 5,427 Ohio State University Comprehensive 1 3,974 Oregon Oregon Health and Science University Clinical 1 1,295 Oregon Evaluation Thomas Jefferson University Clinical 1 1,295 Oregon Evaluation Thomas Jefferson University Clinical 1 3,202 University of Pennsylvania Comprehensive 1 3,202 University of Pennsylvania Comprehensive 1 5,516 University of Pittsburgh at Pittsburgh Comprehensive 1 5,516 Evaluation Eva		·			
University of North Carolina Chapel hill Wake Forest University Health Sciences Comprehensive Case Western Reserve University Ohio State University Comprehensive Ohio State University Comprehensive Oregon Oregon Health and Science University Comprehensive Oregon Fox Chase Cancer Center Comprehensive Clinical Fox Chase Cancer Center Comprehensive Clinical Thomas Jefferson University Clinical Comprehensive Clinical Clini	Namba Canalina		· · · · · · · · · · · · · · · · · · ·		
Wake Forest University Health Sciences	North Carolina	•			
Ohio Case Western Reserve University Comprehensive 1 5,427 Oregon Oregon Health and Science University Clinical 1 1,295 Pennsylvania Fox Chase Cancer Center Comprehensive 1 8,491 Thomas Jefferson University Clinical 1 3,202 University of Pennsylvania Comprehensive 1 7,214 University of Pennsylvania Comprehensive 1 5,510 Wistar Institute Basic 1 2,627 South Carolina Medical University of South Carolina Clinical 1 1,875 Tennessee St. Jude Children's Research Hospital Comprehensive 1 6,455 Vanderbitt University Comprehensive 1 3,440 Texas Baylor College of Medicine Clinical 1 1,456 University of Texas M.D. Anderson Cancer Center Comprehensive 1 10,584 University of Texas San Antonio Health Science Center Clinical 1 1,460 Utah University of Utah Clinical 1 1,583 Virginia University of Virginia Charlottesville Clinical 1 1,563 Virginia University of Wisconsin Madison Comprehensive					
Ohio State University Comprehensive 1 3,974 Oregon Oregon Health and Science University Clinical 1 1,295 Pennsylvania Fox Chase Cancer Center Comprehensive 1 8,491 Thomas Jefferson University Clinical 1 3,202 University of Pennsylvania Comprehensive 1 7,214 University of Pennsylvania Comprehensive 1 5,510 Wistar Institute Basic 1 2,667 South Carolina Medical University of South Carolina Clinical 1 1,875 Tennessee St. Jude Children's Research Hospital Comprehensive 1 6,456 Vanderbilt University Comprehensive 1 6,456 University of Texas M.D. Anderson Cancer Center University of Texas San Antonio Health Science Center University of Texas Southwestern Medical Center Clinical 1 1,468 University of Texas Southwestern Medical Center Clinical 1 1,583 Virginia University of Virginia Charlottesville Virginia Commonwealth University Clinical 1 1,025 Washington Fred Hutchinson Cancer Research Center Comprehensive 1 1,025 Wisconsin University of Wisconsin Madison Comprehensive 1 1,489 Total P30s Planning Grants (P20s) Other P20, P30 & U41	Ohio				
Oregon Oregon Health and Science University Clinical 1 1,295 Pennsylvania Fox Chase Cancer Center Comprehensive 1 8,491 Thomas Jefferson University Clinical 1 3,202 University of Pennsylvania Comprehensive 1 7,214 University of Pittsburgh at Pittsburgh Comprehensive 1 5,510 Wistar Institute Basic 1 2,627 South Carolina Medical University of South Carolina Clinical 1 1,875 Tennessee St. Jude Children's Research Hospital Comprehensive 1 6,223 Vanderbilt University Comprehensive 1 6,458 Texas Baylor College of Medicine Clinical 1 10,584 University of Texas M.D. Anderson Cancer Center Comprehensive 1 10,584 University of Texas Southwestern Medical Center Clinical 1 1,465 Utah University of Virginia Charlottesville Clinical 1 1,583 Virginia University of Virginia Charlottesville Clinical 1 1,2561 W	Onio				- ,
Pennsylvania Fox Chase Cancer Center Thomas Jefferson University Clinical 1 3,202 University of Pennsylvania Comprehensive 1 7,214 University of Pittsburgh at Pittsburgh Comprehensive 1 5,510 Wistar Institute Basic 1 2,627 South Carolina Medical University of South Carolina Clinical 1 1,875 Tennessee St. Jude Children's Research Hospital Comprehensive 1 6,456 Vanderbilt University Comprehensive 1 6,456 University of Texas M.D. Anderson Cancer Center University of Texas San Antonio Health Science Center University of Texas Southwestern Medical Center Clinical 1 1,583 Virginia University of Virginia Charlottesville Clinical 1 1,025 Virginia Commonwealth University Clinical 1 1,025 Virginia Commonwealth University Clinical 1 1,025 Virginia Commonwealth University Center Comprehensive 1 1,025 Virginia Commonwealth University Clinical 1 1,025 Virginia Commonwealth University Comprehensive 1 11,442 Virginia Commonwealth University Comprehensive 1 11,442 Virginia Grants (P20s) Comprehensive 1 2,394 Other P20, P30 & U41	Oregon	,	· · · · · · · · · · · · · · · · · · ·		
Thomas Jefferson University University of Pennsylvania University of Pennsylvania University of Pittsburgh at Pittsburgh Wistar Institute Basic South Carolina Medical University of South Carolina Tennessee St. Jude Children's Research Hospital Vanderbilt University Comprehensive 1 6,225 Vanderbilt University Comprehensive 1 6,455 Baylor College of Medicine University of Texas M.D. Anderson Cancer Center University of Texas San Antonio Health Science Center University of Texas Southwestern Medical Center University of Virginia Charlottesville Virginia University of Virginia Charlottesville Virginia Commonwealth University Comprehensive 1 1,583 Virginia University of Virginia Charlottesville Virginia Commonwealth University Clinical 1 1,025 Comprehensive 1 1,442 Clinical 1 1,583 Clinical 1 1,025 Comprehensive 1 4,897 Total P30s Planning Grants (P20s) Other P20, P30 & U41					8,491
University of Pittsburgh at Pittsburgh Wistar Institute South Carolina Medical University of South Carolina Tennessee St. Jude Children's Research Hospital Vanderbilt University Texas Baylor College of Medicine University of Texas M.D. Anderson Cancer Center University of Texas San Antonio Health Science Center University of Texas Southwestern Medical Center University of Utah University of Virginia Charlottesville Virginia University of Virginia Charlottesville Virginia Commonwealth University Washington Fred Hutchinson Cancer Research Center Wisconsin University of Wisconsin Madison Total P30s Planning Grants (P20s) Other P20, P30 & U41	ĺ	Thomas Jefferson University		1	3,202
Wistar Institute		University of Pennsylvania	Comprehensive	1	7,214
South Carolina Medical University of South Carolina Clinical 1 1,875		University of Pittsburgh at Pittsburgh	Comprehensive	1	5,510
Tennessee					2,627
Vanderbilt University	South Carolina				1,875
Texas	Tennessee				6,223
University of Texas M.D. Anderson Cancer Center University of Texas San Antonio Health Science Center University of Texas San Antonio Health Science Center University of Texas Southwestern Medical Center Clinical 1 1,469 University of Utah University of Utah University of Virginia Charlottesville University of Virginia Commonwealth University Clinical 1 2,561 University Of University Of University University Clinical 1 1,025 University of Wisconsin University of Wisconsin Madison Comprehensive 1 1,489 University Of University					
University of Texas San Antonio Health Science Center University of Texas Southwestern Medical Center University of Texas Southwestern Medical Center Ulan Ulan University of Utah University of Utah University of Virginia Charlottesville University of Virginia Commonwealth University Of Wisconsin University Of Wisconsin Madison University of Wisconsin Madison University of Wisconsin Madison University Of Wisconsin University Of Wisconsin Madison University Of Wisconsin Medison Un	Texas				
University of Texas Southwestern Medical Center Clinical 1 1,600			•		
Utah University of Utah Clinical 1 1,583 Virginia University of Virginia Charlottesville Clinical 1 2,561 Virginia Commonwealth University Clinical 1 1,025 Washington Fred Hutchinson Cancer Research Center Comprehensive 1 11,442 Wisconsin University of Wisconsin Madison Comprehensive 1 4,897 Total P30s 66 283,125 Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337					·
Virginia University of Virginia Charlottesville Clinical 1 2,561 Virginia Commonwealth University Clinical 1 1,025 Washington Fred Hutchinson Cancer Research Center Comprehensive 1 11,442 Wisconsin University of Wisconsin Madison Comprehensive 1 4,897 Total P30s 66 283,125 Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337	Litab	•			
Virginia Commonwealth University Clinical 1 1,025 Washington Fred Hutchinson Cancer Research Center Comprehensive 1 11,442 Wisconsin University of Wisconsin Madison Comprehensive 1 4,897 Total P30s 66 283,125 Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337					
Washington Fred Hutchinson Cancer Research Center Comprehensive 1 11,442 Wisconsin University of Wisconsin Madison Comprehensive 1 4,897 Total P30s 66 283,125 Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337	virginia				·
Wisconsin University of Wisconsin Madison Comprehensive 1 4,897 Total P30s 66 283,125 Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337	Washington				
Total P30s 66 283,125 Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337					
Planning Grants (P20s) 12 2,394 Other P20, P30 & U41 0 10,337	**1000113111		Comprehensive		
Other P20, P30 & U41 0 10,337					
		s	66		

Specialized Programs of Research Excellence, Fiscal Year 2010

(Dollars in Thousands)


In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers.

Each SPORE is focused on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. For more information, see http://trp.cancer.gov.

Mechanism	Site	No.	Amount
P50 SPOREs	Brain	3	\$5,053
	Breast	9	18,637
	Cervical	1	2,300
	Endometrial	1	500
	Genitourinary	1	2,233
	Gastrointestinal	6	12,543
	Head and Neck	4	8,593
	Kidney	1	2,300
	Leukemia	2	4,458
	Lung	7	15,645
	Lymphoma	4	7,659
	Myeloma	2	4,600
	Ovarian	5	9,632
	Pancreatic	2	4,600
	Prostate	9	20,636
	Sarcoma	1	2,300
	Skin	4	9,133
	Uterine	1	2,300
	Subtotal	63	133,122
P20	Gastrointestinal		488
	Total P20		488
Co-funded	Head & Neck with NIDCR		200
	Total Co-funded		200
Total NCI SPO	REs and NCI SPORE Funding	63	\$133,810

NRSA Predoctoral and Postdoctoral Trainees Fiscal Years 1997-2010


(Full Time Trainee Positions)



Construction/Renovation Funding and Building & Facilities Funding Fiscal Years 1999 - 2010

(Dollars in Thousands)

Construction/Renovation grants and contracts were used by grantees to build infrastructure. The grants (C06s) provide matching Federal funds for up to 50% of allowable costs for construction or major remodeling to create new facilities for cancer research. Although the NCI has the authority to fund Construction grants, Congress has not appropriated funds to this program for NCI since FY 2003. In FY 2005, NCI began to recieve Building & Facilities funding to use specifically for repairs and improvements at the NCI - Frederick facility.



Grant and Contract Awards by State Fiscal Year 2010 (Dollars in Thousands)

(Dollars in Thousands)	Grants Contracts		Total			
<u>State</u>	No	Amount	No	Amount	No	Amount
Alabama	64	\$33,627	4	\$4,156	68	\$37,783
Arizona	64	29,250	3	600	67	29,850
Arkansas	24	9,542	1	150	25	9,692
California	841	465,027	34	24,636	875	489,663
Colorado	84	28,974	2	1,714	86	30,688
Connecticut	89	37,736	1	2,479	90	40,215
Delaware	2	1,281		_,	2	1,281
District of Columbia	66	28,770	17	9,988	83	38,758
Florida	171	66,665	3	1,939	174	68,604
Georgia	100	34,482	11	6,263	111	40,745
Hawaii	19	15,454	2	3,882	21	19,336
Idaho	1	212	_	0,002	1	212
Illinois	255	103,315	6	5,031	261	108,346
Indiana	71	23,876	1	200	72	24,076
lowa	42	15,578	2	4,602	44	20,180
Kansas	20		2		22	
		8,433		1,150		9,582
Kentucky	62	17,424	1	1,355	63	18,778
Louisiana	38	10,676	2	1,935	40	12,611
Maine	5	3,554	00	050 705	5	3,554
Maryland	231	123,899	68	352,705	299	476,603
Massachusetts	635	385,943	17	6,782	652	392,725
Michigan	207	121,077	5	8,143	212	129,221
Minnesota	192	101,279	6	3,939	198	105,218
Mississippi	5	1,589			5	1,589
Missouri	106	48,093	7	4,509	113	52,601
Montana	4	1,278	1	199	5	1,477
Nebraska	40	15,447			40	15,447
Nevada	7	1,979			7	1,979
New Hampshire	50	23,010	2	1,446	52	24,456
New Jersey	85	29,370	4	4,997	89	34,367
New Mexico	26	13,091	1	2,253	27	15,344
New York	581	285,121	9	7,662	590	292,782
North Carolina	260	127,780	8	1,949	268	129,729
North Dakota	4	1,155			4	1,155
Ohio	230	96,745	9	7,913	239	104,658
Oklahoma	12	3,666	1	130	13	3,796
Oregon	43	16,179			43	16,179
Pennsylvania	424	203,730	7	4,115	431	207,845
Rhode Island	40	14,087	,	66	40	14,153
South Carolina	47	15,967		00	47	15,967
South Dakota	3	2,323			3	2,323
Tennessee	202	106,004	1	200	203	106,204
Texas	520	241,149	9	1,442	529	242,590
	54		2			
Utah		22,668	2	2,861	56	25,530
Vermont	5	2,964	10	00.010	5	2,964
Virginia	97	59,635	13	28,816	110	88,451
Washington	217	134,733	3	11,156	220	145,889
West Virginia	14	3,698		4 005	14	3,698
Wisconsin	113	49,672	2	1,865	115	51,536
Wyoming	1	72			1	72
Subtotal	6,473	3,187,274	267	523,228	6,740	3,710,502
Guam	1	1,631			1	1,631
Puerto Rico	5	3,069			5	3,069
Total	6,479	3,191,974	267	523,228	6,746	3,715,202

Excludes STAMP, NRSA TAP, Loan Repayment Program, Foreign Contracts and Grants, Program Evaluation, and other assessments and miscellaneous expenses.

Grant and Contract Awards by Country Fiscal Year 2010

(Dollars in Thousands)

	ŕ					
	Gr	ant	Con	tract	Tot	al
<u>Country</u>	<u>No</u>	<u>Amount</u>	<u>No</u>	<u>Amount</u>	<u>No</u>	<u>Amount</u>
Australia	6	\$2,703			6	\$2,703
Belgium	1	423			1	423
Brazil	0	27			0	27
Canada	25	10,075	2	\$1,044	27	11,119
Costa Rica			1	4,395	1	4,395
Finland			1	391	1	391
France	2	1,540			2	1,540
Germany	1	380			1	380
India	1	228			1	228
Ireland	1	201			1	201
Israel	6	1,200			6	1,200
Mexico	0	121			0	121
Spain	4	964			4	964
Sweden	1	386			1	386
Switzerland	2	659			2	659
Turkey	0	26			0	26
United Kingdom	6	1,685			6	1,685
Total Foreign	56	20,619	4	5,830	60	26,448

 ${\bf Excludes\ STAMP,\ NRSA\ TAP,\ Loan\ Repayment\ Program,\ Program\ Evaluation,\ and\ otherassessments\ and\ miscellaneous\ expenses.}$

Institutions Receiving More than \$15 Million in NCI Support, FY 2010 (Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$27,880	\$1,316	\$29,196
Arizona	University of Arizona	21,305	75	21,380
California	Burnham Institute for Medical Research	17,820		17,820
	City of Hope's Beckman Research Institute	23,403		23,403
	National Childhood Cancer Foundation	41,382		41,382
	Stanford University	57,975		57,975
	University of California System	181,082	1,477	182,559
	University of Southern California	42,029	3,652	45,681
Colorado	University of Colorado Health Sciences Center	20,159	1,564	21,723
Connecticut	Yale University	35,186	1,504	35,186
District of Columbia	Georgetown University	22,637	3,397	26,034
Florida	H. Lee Moffitt Cancer Center & Research Institute	36,667	1,248	37,915
Georgia	Emory University	21,652	2,289	23,941
Hawaii	University of Hawaii	14,029	1,381	15,410
Illinois	Northwestern University	29,435	1,501	29,435
11111015	University of Chicago	32,508	474	32,982
	, ,	19,670	4/4	19,670
leure	University of Illinois at Chicago		4 600	
lowa	University of lowa	13,937	4,602	18,539
Maryland	The Johns Hopkins University	85,678	000 040	85,678
	SAIC-Frederick, Inc.		220,348	220,348
	Westat, Inc.		38,979	38,979
Massachusetts	Beth Israel Deaconess Medical Center	22,761		22,761
	Brigham and Women's Hospital	62,520		62,520
	Dana-Farber Cancer Institute	86,901		86,901
	Frontier Science & Tech Research Foundation	15,828		15,828
	Harvard University	31,573		31,573
	Massachusetts General Hospital	42,980	1,800	44,780
	Massachusetts Institute of Technology	30,145		30,145
	University of Massachusetts Medical School Worcester	20,057	50	20,107
Michigan	University of Michigan at Ann Arbor	88,301		88,301
	Wayne State University	17,042	4,962	22,003
Minnesota	Mayo Clinic in Rochester	61,425	817	62,242
	University of Minnesota	36,139	2,963	39,102
Missouri	Washington University	41,628	1,351	42,979
New Hampshire	Dartmouth College	21,914	247	22,161
New York	Columbia University Health Sciences	26,794		26,794
	Mount Sinai School of Medicine	17,807		17,807
	New York University	16,922		16,922
	Roswell Park Cancer Institute Corporation	33,924		33,924
	Sloan-Kettering Institute for Cancer Research	79,641	2,092	81,732
	University of Rochester	16,694	,	16,694
	Yeshiva University	27,270		27,270
North Carolina	Duke University	45,626	24	45,650
rtorar oaronna	University of North Carolina at Chapel Hill	51,350	- '	51,350
	Wake Forest University Health Sciences	15,834		15,834
Ohio	Case Western Reserve University	20,300		20,300
Onio			267	
Pennsylvania	Ohio State University Fox Chase Cancer Center	48,108 20,372	267 1,016	48,375 21,388
i eiiisyivaiia	University of Pennsylvania		1,459	55,265
		53,806	1,439	
Tannasaa	University of Pittsburgh St. Jude Children's Research Hospital	52,190		52,190
Tennessee	· •	26,085		26,085
T	Vanderbilt University	69,896		69,896
Texas	Baylor College of Medicine	34,479		34,479
	University of Texas Health Science Center at San Antonio	16,042	25-	16,042
	University of Texas, MD Anderson Cancer Center	126,632	222	126,855
	University of Texas, SW Medical Center at Dallas	20,187		20,187
Utah	University of Utah	20,885	2,861	23,747
Virginia	American College of Radiology	29,148		29,148
	University of Virginia at Charlottesville	14,098		14,098
Washington	Fred Hutchinson Cancer Research Center	87,892	10,995	98,887
	University of Washington	30,460		30,460
Wisconsin	University of Wisconsin	33,175		33,175
	Total	\$2,359,263	\$311,929	\$2,671,192

Includes Manpower Development Grants


Appropriations of the NCI 1938-2010 (In Whole Dollars)

1938 - 1999	\$41,661,018,220	
2000	3,332,317,000	prior to reductions in PL 106-113 (-\$17,763,000 for across the board reduction). Includes \$245,804,000 of AIDS funding.
2001	3,757,242,000	prior to reductions in PL 106-554(-\$2,005,000 for across-the-board reduction). Includes -\$711,000 Secretary's 1% transfer, -\$781,000 transfer for Office of Human Research Protection and -\$24,000 lapse. Includes \$255,960,000 of AIDS funding.
2002	4,190,405,000	prior to reductions in PL 107-116(-\$4,524,000 via the Secretary's 1% transfer authority, -\$2,054,000 for the enacted rescission, -\$7,118,000 administrative reduction and -\$8,000 lapse). Includes \$254,396,000 of AIDS funding.
2003	4,622,394,000	prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and -\$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004	4,770,519,000	prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000
2005	4,865,525,000	prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of
2006	4,841,774,000	prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,866,000 of AIDS funding.
2007	4,797,639,000	prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,866,000 of AIDS funding.
2008	4,827,556,000	Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.
2009	4,968,973,000	prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4000 lapse). Includes \$265,882,000 of AIDS funding.
2010	5,103,388,000	prior to -\$760,000 HHS Secretary's transfer ,-\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.
1938-2010	91,738,750,220	

Fiscal	
Year	Request
1974	640,031,000
1975	750,000,000
1976	898,500,000
1977	948,000,000
1978	955,000,000
1979	1,036,000,000
1980	1,055,000,000
1981	1,170,000,000
1982	1,192,000,000
1983	1,197,000,000
1984	1,074,000,000
1985	1,189,000,000
1986	1,460,000,000
1987	1,570,000,000
1988	1,700,000,000
1989	2,080,000,000
1990	2,195,000,000
1991	2,410,000,000
1992	2,612,000,000
1993	2,775,000,000
1994	3,200,000,000
1995	3,600,000,000
1996	3,640,000,000
1997	2,977,000,000
1998	2,702,500,000
1999	3,191,000,000
2000	3,873,000,000
2001	4,135,000,000
2002	5,030,000,000
2003	5,690,000,000
2004	5,986,000,000
2005	6,211,000,000
2006	6,170,000,000
2007	5,949,714,000
2008	5,865,788,000
2009	6,028,386,000
2010	7,193,393,000
2011	6,199,666,000
2012	5,869,857,000

The National Cancer Act in December 1971, included a provision for the Director, NCI to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

Bypass Requests and Appropriations of the NCI Fiscal Years 1974-2012



^{*} This represents the funding available to NCI under the FY 2011 continuing resolution.


Comparison of Dollars, Positions, and Space Fiscal Years 1999-2010


Funds are obligations against the annual appropriation in millions of dollars.

FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.

The increase in FTEs in FY 2000 is due to the fact that 195 contract staff were converted to NCI appointments.

Space is in thousands of square feet, excluding NCI-Frederick.





Fiscal Year	Full Time Permanent	Other than Full Time Permanent	Training Fellows	Total Personnel Resources
real	Appointment	remanent	reliows	nesources
1999	1,941	628	1,060	3,629
2000	2,139	831	1,202	4,172
2001	2,224	912	963	4,099
2002	2,250	979	949	4,178
2003	2,193	1,073	1,191	4,457
2004	2,083	990	1,232	4,305
2005	1,959	882	1,077	3,918
2006	2,579	289	1,113	3,981
2007	2,421	498	1,111	4,030
2008	2,075	920	1,016	4,011
2009	2,118	959	1,058	4,135
2010	2,148	1,011	1,073	4,232

Fiscal Year	NCI	NIH	% NCI of NIH
1996	225,360	1,411,860	16%
	,		
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%
2004	266,975	2,840,384	9%
2005	265,907	2,909,381	9%
2006	253,666	2,902,183	9%
2007	253,666	2,904,536	9%
2008	258,499	2,928,300	9%
2009	265,882	3,019,279	9%
2010	272,130	3,085,597	9%

